PULMONARY PATHOLOGY

Kenneth Alonso, MD, FACP

Rapidly fatal thoracic injuries

- Airway obstruction
- No audible breath sounds
- Gurgling
- Open pneumothorax
- Absent breath sounds on affected side
- No mediastinal shift
- Tension pneumothorax
- Absent breath sounds on affected side
- Mediastinal shift

Rapidly fatal thoracic injuries

- Flail chest
- Affected chest moves paradoxically with respiration
- Pneumothorax often associated
- Hemothorax
- Diminished breath sounds
- Hypotension and tachycardia
- Caridac tamponade
- Normal breath sounds
- Hypotension
- Pulsus paradoxus
- Distended neck veins

Embryology

- At 5-16 weeks, conducting bronchi form (canalicular stage).
- Before 16 weeks the fetus cannot survive outside the womb as there is no structure for gas exchange
- At 17-26 weeks, respiratory bronchioles form (pseudoglandular stage);
- The production of surfactant from type II pneumocytes begins as early as week 24.
- At 24-26 weeks, terminal bronchioles reach primordial air sacs; the lung is well vascularized.
- Gas exchange is now possible outside the womb
- Steroids may accelerate maturation after 26 weeks gestation

Embryology

- From 27 weeks to 36 weeks, the blood-air barrier is established between the epithelial layer (Type I pneumocytes) and capillaries. (saccular stage)
- Type II pneumocytes are distributed among the Type I pneumocytes. Surfactant production increases
- Alveolar increase begins at week 32 (alveolar stage).
- Alveoli increase in number and volume until 2 years of age



http://basenat.u707.jussieu.fr/site_respirare/index.php?option=com_content&view=article&id=59&Itemid=30&lang=en&showall=1
Accessed 01/10/2020

Laryngeal atresia

http://www.sonoworld.com/fetus/page.aspx?id=1250
Accessed 01/10/2020

Results from failure of the laryngeal lumen to recanalize.

Congenital or acquired narrowing of the airway that may affect the supraglottis, glottis, and/or subglottis

Features:

1) Obstruction of the upper fetal airway
2) Dilated airways below the obstruction
3) Enlarged lung and echogenic (due to accumulation of fluid)
4) Flattened or inverted diaphragm
5) Fetal ascites
6) Edema

Lung hypoplasia

Figure 14. lunghypoplasia. Available at http://www.brown.edu/Courses/Digital_Path/systemic_path/pulmonary/ph2.html

Incomplete development of lung tissue.

Noted are the carina, a malformed bronchial stump, and absent or poorly differentiated distal lung tissue.

Associated with other cardiac, gastrointestinal, or skeletal abnormalities in 50% of cases.

Polyhydramnios.

Lung hypoplasia

- May be asymptomatic or may present with severe respiratory distress
- Older children may present with dyspnea and cyanosis may be present upon exertion, or have a history of respiratory infections.
- The external chest may appear normal or may be small and bell shaped, with or without scoliosis.
- A mediastinal shift is observed toward the involved side, and dullness upon percussion is heard over the displaced heart.
- Breath sounds may be decreased or absent on the side of hypoplasia, especially over the bases and axilla

Lung hypoplasia

- The Potter facies (hypertelorism, epicanthus, retrognathia, depressed nasal bridge, low set ears) suggest lung hypoplasia caused by the associated renal defects
- When the etiology of the hypoplasia is a neuromuscular disease, the patient may have myopathic facies, with a V-shaped mouth, muscle weakness, and growth retardation

Physical examination

- Detection of cyanosis, tachypnea, crackles, whispered pectoriloquy or increased tactile fremitus have κ values of 0.36, 0.25, 0.41, 0.11, and 0.10 respectively. They are not easily reproduced.
- Dullness to percussion or wheezes have κ values of 0.5.
- Clubbing must be determined from measurement, not observation.
- Clubbing is present if the paronychial angle >192°.

Spirometry



Representative spirograms (upper panel) and expiratory flow-volume curves (lower panel). Normal (A), obstructive (B), and restrictive (C) patterns.

Fig. e9-10 Accessed 04/27/2010

Pulmonary flow loops

- The expiration curve of an air-filled lung is steeper than the inspiration curve.
- The difference in the curves is hysteresis.
- The expiration limb is determined by lung compliance only (and depends upon the amount of elastic tissue present).
- Surface tension alters the inspiration limb on the air-filled lung.
- The starting point is deflation (low lung volume, low alveolar radius).
- Elevated pressures are required to open the alveoli (and overcome intermolecular forces at the air-liquid interface).

Dynamic measurements

- Normal forced vital capacity in 70kg man (FVC): 5L
- Based on sex, age, body habitus
- Normally 65mg/kg
- Functional capacity of lung
- Normal forced expiratory volume in 70kg man
- At 1 second (FEV_1): 4L
- At 3 seconds (FEV_3): 5L
- Measures large and mid-size airway resistance
- Normal peak expiratory flow rate (PEFR) in a 70kg man: 500L/min
- Flow rate of first 0.20 seconds of forced expiration
- Measures small airway resistance

Dynamic measurements

- Total lung capacity (TLC) is the volume of air present in the chest after full inspiration.
- During quiet ventilation, the volume of air inspired and expired in one breath is the tidal volume (TV)
- Normal 500-750 mL.

Dynamic measurements

- The volume of air left in the lungs at the end of quiet expiration is the functional residual capacity (FRC).
- The amount remaining at the end of maximal expiration is the residual volume (RV).
- Measured by plethysmography or inert gas diffusion
- Age, sex, body habitus dependent
- RV depends upon on expiratory muscle strength in addition to the elastic recoil of the chest wall and airway closure.
- Lung functions as bellows

Dynamic measurements

- TLC <80% of predicted
- Restrictive lung disease
- If $D_{L_{CO}}$ (measurement of gas diffusion) normal
- Asthma
- Left-to-right shunts
- If $D_{L_{CO}}$ diminished
- Pulmonary edema
- Interstitial lung disease
- Pulmonary embolism
- Pulmonary hypertension

Lung resistance

- The medium sized bronchi are arranged in series and are the sites of highest airway resistance.
- Small airways are arranged in parallel.
- Reduces airway resistance
- Turbulent flow is converted to laminar flow
- Large cross-sectional area
- Favors gas exchange

Lung resistance

- Parasympathetic stimulation (muscarinic receptors) produces airway constriction.
- Smooth muscle is under tonic parasympathetic control.
- Sympathetic stimulation (β_2 receptors) produces airway relaxation.
- Its principal effect is on small airways.

Lung resistance

- In normal lungs, forced expiration generates intrapulmonary and intrapleural pressures higher than normal.
- The airways and alveoli do not collapse under that condition as the transmural pressure remains positive.

Lung resistance

- In restrictive lung disease, forced expiration generates normal intrapleural pressure
- However, there is diminished elastic recoil of airways and alveoli.
- Transmural pressure across the alveoli remains positive and they remain open.
- The transmural pressure gradient reverses across airways and they collapse.
- Airway resistance to flow increases.
- Increases in gas viscosity (diving at depth, dehumidified air) also produce increases in resistance.

Gas transfer

- The volume of gas diffused is inversely proportional to membrane thickness.
- The diffusion coefficient of a gas is directly proportional to its solubility and inversely proportional to the square root of its molecular weight.
- Capillary blood flow limits O_2 uptake.
- Under steady state conditions, approximately 250 mL of O_2 per minute are transferred to the pulmonary circulation (VO_2) while 200 mL of carbon dioxide per minute are removed (VCO_2).

Oxygen levels

- Sensing of increased (hyperoxia) or decreased (hypoxia) O_2 level occurs through specialized chemoreceptor cells that regulate cardiovascular and ventilatory rates.
- (1) Carotid bodies (glomus) are highly vascularized organs, located at the bifurcations of the common carotid arteries.
- Lie in contact with sensory efferents of carotid sinus nerve.
- Acetylcholine and norepinephrine mediation.

Oxygen levels

- (2) Neuroepithelial bodies are located at airway bifurcations.
- Synapse with afferent and efferent vagal nerve neurons.
- Serotonin mediation.
- In addition, all nucleated cells sense O_2 concentration and respond to reduced O_2 availability acutely (within minutes) through the activation of pre-existing proteins and chronically (within hours) through the regulation of gene transcription.

Oxygen levles

- Peripheral vessels dilate in response to low oxygen
- The vessels of the pulmonary vasculature constrict to shunt blood away from the poorly ventilated region
- Hypoxic pulmonary vasoconstriction is a fast response that occurs in pulmonary arteries and veins but is greatest in small resistance arteries.
- It is intrinsic to pulmonary vasculature smooth muscle cells

Oxygen levels

- Hypoxic vasodilation is another fast response that increases perfusion of blood to the O_2-deprived tissues.
- This is particularly well evoked in coronary and cerebral vessels.

Respiratory Control System

- Controlled from the medulla.
- Dorsal respiratory nucleus (midlateral part of solitary nucleus) has inspiratory function.
- The ventral respiratory nucleus is expiratory
- Functions as an oscillator, engaged in reciprocal inhibition with the inspiratory center.
- The chemosensitive area lies at the site of attachment of CN IX to the brainstem, where the choroid plexus extends through the lateral aperture of the 4^{th} ventricle.
- Sensitive to H^+

Respiratory control system

- The medial parabrachial nucleus (adjacent to the cerulean nucleus) has a pacemaker function.
- Stimulated by the amygdala.
- Receptors in the airway innervated by:
- Slowly adapting myelinated vagal fibers
- Rapidly adapting myelinated vagal fibers
- Unmyelinated C fibers near pulmonary vessels.
- Slowly adapting receptors can be activated by lung inflation.
- Rapidly adapting receptors can be activated by acidosis and chemicals such as histamine and result in cough or even hyperpnea.

Normal chest anatomy



Fig. e24-1 Accesed 03/17/2010

1. Trachea. 2. Carina. 3. Right atrium. 4. Right hemi-diaphragm. 5. Aortic knob. 6. Left hilum. 7. Left ventricle. 8. Left hemi-diaphragm (with stomach bubble). 9. Retrosternal clear space. 10. Right ventricle. 11. Left hemi-diaphragm (with stomach bubble). 12. Left upper lobe bronchus.

Normal chest anatomy



Source: Fauci AS, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J: *Harrison's Principles of Internal Medicine*, 17th Edition: http://www.accessmedicine.com

Fig. e24-2 Accessed 03/17/2010

1. Superior vena cava. 2. Trachea. 3. Aortic arch. 4. Ascending aorta. 5. Right mainstem bronchus. 6. Descending aorta. 7. Left mainstem bronchus. 8. Main pulmonary artery.

Normal chest anatomy

C

9. Heart.
10. Esophagus.
11. Pericardium.
12. Descending aorta.

Fig. e24-2 Accessed 03/17/2010


Central compartment
Primary bronchus
Secondary bronchus
Tertiary bronchus
Bronchiole
Terminal bronchiole
Alveoli
Large bronchus
Ciliated cell
Mucous cell
Neuro-endocrine cell
Basal cell
Basement membrane
Peripheral compartment
Respiratory bronchiole
Alveolus
Respiratory bronchiole
Clara cell
Ciliated cell
Basement membrane
Interstitium
Type I pneumocyte
Type II pneumocyte
Alveolus
Respiratory bronchiole
Alveolar duct
Alveolus
Alveolus

Fig. 1.10

Causes of dyspnea

- Resistance to flow
- Airway obstruction
- Resistance to lung expansion
- Interstitial or parenchymal disease
- Edema (BNP> 100 mg/dL)
- Resistance to chest wall expansion or diaphragm excursion
- Fatigue
- Pleural effusion or fibrosis
- V/Q mismatch
- Pulmonary embolism
- Pulmonary hypertension

Diagnostic uses

- In obstructive airway disease, FVC and FEV at 1 second are decreased as well as the ratio FEV_1/FVC.
- In restrictive lung disease, FVC and FEV_1 are decreased; the ratio of FEV_1/FVC increases.
- If FEV_1/FVC <75%, and respond to bronchodilator, is asthma
- If FEV_1/FVC <75%, and does not respond to bronchodilator, is COPD
- If DLCO normal, is bronchitis
- If DLCO diminished, is emphysema

Role of surfactant

- Surfactant reduces surface tension at the air-liquid barrier in alveoli.
- With normal levels of surfactant, the lungs retain up to 40% of the residual air volume after the first breath.
- Subsequent breaths require less effort to maintain patency (no atelectasis).
- Surfactant production (type II alveolar cells) accelerates in 35th week of gestation.
- Minimal quantity present before 32 weeks

Surfactant

- Pulmonary surfactant consists of:
- 90% phospholipids
- Dipalmitoyl phosphatidylcholine (lecithin)
- Phosphatidylglycerol,
- 10% surfactant associated glycoproteins
- SP-A and SP-D (hydrophilic) are collectins and deal with innate immunity
- SP-B and SP-C (hydrophobic) affect surface tension
- Packaged into lamellar bodies and secreted into the alveolar space where it unravels to form a monolayer on alveolar surfaces
- Enters amniotic fluid

Surfactant

- Synthesis increased by:
- Cortisol
- Thyroxine
- Synthesis decreased by:
- Insulin

SURFACTANT DISORDERS

Respiratory distress syndrome

- Usually develops in the first 24 hours after birth.
- If premature newborns still have breathing problems by the time they reach 36 weeks gestation, they may be diagnosed with bronchopulmonary dysplasia
- Alveoli are poorly developed.
- There may be disruption of alveolar septation at the saccular stage (bronchopulmonary dysplasia)
- Necrotic cellular debris (fibrin and type II cells) in terminal bronchioles and alveoli are incorporated within eosinophilic membranes (leaked plasma) lining the respiratory bronchioles, alveolar ducts, and alveoli.

Respiratory Distress Syndrome



Ground glass appearance on chest x-ray.

By Mikael Häggström, M.D.- Author info- Reusing imagesWritten informed consent was obtained from a parent of the individual, including for online publication. - Own work, CC0, https://commons.wikimedia.org/w/index.php?curid=71691505
Accessed 01/10/2020
Acessed 01/10/2020

Hyaline mebranes



Type II pneumocyte hyperplasia with hyaline membrane formation. Necrotic material and inflammatory debris in alveolar spaces.

https://thoracickey.com/wp-content/uploads/2016/10/f0117-01.jpg Accessed 01/10/2020

Respiratory distress syndrome

- Surfactant replacement therapy is cornerstone of therapy.
- High O_2 concentrations in the inspired air may be required
- Hypoxemia due to perfusion-ventilation mismatch in atelectatic lungs
- O_2 delivered at positive pressure
- To open atelectatic lung.
- Some newborns recover and do not develop bronchopulmonary dysplasia.

Bronchopulmonary dysplasia



Dysplastic alveoli with severe fibrosis at upper left, compensatory emphysema of less damaged area at bottom right.

http://www.meddean.luc.edu/lumen/bbs/p/ppi15.html
Accessed 01/10/2020

Respiratory distress syndrome

- High O_2 concentrations in the inspired air for more than 28 days may lead to:
- Retrolental fibroplasia (retinopathy of prematurity)
- Hypoxemia may lead to:
- Intraventricular hemorrhage (cerebrum)
- Patent ductus arteriosus remaining open
- Necrotizing enterocolitis

Retinopathy of prematurity

- Leading cause of childhood blindness.
- Due both to VEGF expression in response to hypoxia as well as from direct O_2 toxicity.
- Retina is vascularized in stages circumferentially about central retinal artery and optic nerve.
- Vascularized last is temporal crescent of retina.
- In the premature infant, there is abnormal blood vessel growth followed by fibrosis, particularly in the peripheral retina.
- May lead to retinal detachment.
- Peripheral retinal ablation is principal treatment.

Retinopathy of prematurity



A. There is a thick ridge separates the posterior vascularized retina from the avascular anterior. There is a section of hemorrhage immediately anterior to the ridge. B. A wider view of the ridge, offering a better depiction of its raised dimensions. There is fibrovascular proliferation on the posterior edge.
https://webeye.ophth.uiowa.edu/eyeforum/cases/286-retinopathy-of-prematurity.htm Accessed 02/20/2020

Steroid therapy

- Antenatal glucocorticoid therapy leads to improvement in neonatal lung function both in mechanics and gas exchange:
- By enhancing maturational changes in lung architecture
- By inducing lung enzymes that play a role in biochemical maturation.
- Alter production of surfactant binding proteins
- Enhance fetal lung antioxidant enzymes.
- Are not administered before 24 weeks gestation.

Table 1. Neonatal and Infant Mortality for Singleton Births From 34 Weeks of Gestation to 41 Weeks of Gestation

		Neonatal Mortality: Neonatal Deaths per 1,000 Births			Infant Mortality: Infant Deaths per 1,000 Births		
GA, Week	Total	Count	Rate	RR (95% CI)	Count	Rate	RR (95% CI)
34	50,717	359	7.1	9.5 (8.4–10.8)[a]	599	11.8	5.4 (4.9–5.9)[a]
35	85,218	405	4.8	6.4 (5.6–7.2)[a]	732	8.6	3.9 (3.6–4.3) [a]
36	156,692	437	2.8	3.7 (3.3–4.2)[a]	890	5.7	2.6 (2.4–2.8)[a]
37	320,169	546	1.7	2.3 (2.1–2.6)[a]	1,323	4.1	1.9 (1.8–2.0)[a]
38	674,892	700	1.0	1.4 (1.3–1.5)[a]	1,842	2.7	1.00 (reference)
39	966,281	721	0.8	1.00 (reference)	2,118	2.2	0.9 (0.9–1.0)
40	821,934	625	0.8	1.0 (0.9–1.1)	1,704	2.1	0.9 (0.9–1.0)
41	407,593	326	0.8	1.1 (0.9–1.2)	888	2.2	1.1 (1.0–1.1)

Abbreviations: GA, gestational age; RR, relative risk.

[a] $P<.001$ when compared with the reference group of 39 weeks of gestation deliveries.

Reprinted from Reddy UM, Ko CW, Raju TN, Willinger M. Delivery indications at late-preterm gestations and infant mortality rates in the United States. Pediatrics 2009;124:234–40.

Evaluation of fetal lung maturity

- Amniocentisis to evaluate fetal lung maturity should now be rarely needed
- May lead to premature delivery
- May lead to premature rupture of membranes (risk for infection)
- Test results are not predictive of who will develop respiratory distress
- Fetuses delivered at 39 weeks gestation have better overall survival and fewer co-morbidities
- The ACOG recommends amniocentesis and testing for fetal lung maturity only in those cases where the time of gestation is unclear

Times for delivery

- 32-38 weeks, Twin gestations
- 34-39 weeks, Congenital anomalies
- 34-35 weeks,
- Placenta accrete, increta, and percreta
- Poorly controlled diabetes mellitus
- Severe eclampsia (at the earliest)
- Premature rupture of membranes (at the earliest)
- 36-37 weeks,
- Placenta previa
- Previous classical section
- Mild eclampsia

Times for delivery

- 37-38 weeks,
- Previous myomectomy (who require a cesarean delivery)
- Chronic or gestational hypertension
- Diabetes mellitus with vascular disease
- 38-39 weeks,
- Uncomplicated fetal growth restriction
- If there are comorbidities or concurrent complications such as oligohydramnios, then delivery may need to occur as early as 34 weeks.

- Uncomplicated diabetes mellitus and gestational diabetes mellitus

Tests for evaluation of fetal lung maturity

- The ACOG (in 2008) recommended the following in a cascade fashion:
- 1. Fluorescence polarization
- 2. Lamellar body count
- 3. Lecithin-sphingomyelin ratio
- 4. Phosphatidylglycerol presence
- Proceed from one to the next until maturity demonstrated (or delivery)
- Testing is not initiated before 32 weeks of gestation
- Foam stability test is of historical interest

Fluorescence polarization test

- Uses polarized light to quantitate the competitive binding of a probe to both albumin and surfactant in amniotic fluid;
- Is a true direct measurement of surfactant concentration.

Lecithin/sphingomyelin

- The concentrations of lecithin and sphingomyelin in amniotic fluid are approximately equal until 32- 33 weeks of gestation
- The concentration of lecithin begins to increase significantly after 32-33 weeks while the sphingomyelin concentration remains about the same.
- The measurement of sphingomyelin serves as a constant comparison for control of the relative increases in lecithin as the volume of amniotic fluid cannot be accurately measured clinically.

Phosphatidylglycerol

- Phosphatidylglycerol is a minor constituent of surfactant.
- It begins to increase appreciably in amniotic fluid several weeks after the rise in lecithin.
- Because phosphatidylglycerol enhances the spread of phospholipids on the alveoli, its presence indicates an advanced state of fetal lung development and function.
- Lecithin, sphingomyelin, and phosphatidyl-glycerol are measured by thin layer chromatography.

Foam stability index

- The foam stability index is a rapid predictor of fetal lung maturity based upon the ability of surfactant to generate stable foam in the presence of ethanol.
- The discriminating value indicative of lung maturity is usually set at ≥47.
- A positive result virtually excludes the risk of respiratory distress;
- However, a negative test often occurs in the presence of mature lungs.
- The presence of blood or meconium interferes with results.
- Silicone produces a false foam.

Test	Positive discriminating value	Predictive value for pulmonary maturity when test is mature*	Predictive value for pulmonary immaturity when test is immature*	Pro's and con's
FLM-TDx	>55 mg/g of albumin	96-100 percent	47-61 percent	Results affected by blood and meconium. Can use a vaginal pooled sample. Minimal inter/ intraassay variability. Simple test.

Test	Positive discriminating value	Predictive value for pulmonary maturity when test is mature*	Predictive value for pulmonary immaturity when test is immature*	Pro's and con's
Lamellar body count	>50,000/ul	97-98 percent	29-35 percent	Results affected by blood but not by meconium. Cannot use a vaginal pooled sample.

Test	Positive discriminating value	Predictive value for pulmonary maturity when test is mature*	Predictive value for pulmonary immaturity when test is immature*	Pro's and con's
Lecithin sphingomyelin ratio	> 2.0	95-100 percent	33-50 percent	Large laboratory variation. Results affected by blood and meconium. Avoid use of a vaginal pooled sample.

Test	Positive discriminating value	Predictive value for pulmonary maturity when test is mature*	Predictive value for pulmonary immaturity when test is immature*	Pro's and con's
Phosphatidyl-glycerol	Present (typically greater than 3 percent of total phospholipids)	95-100 percent	23-53 percent	Not affected by blood, meconium. Bacteria can give a false positive in vaginal pool samples.

Pulmonary alveolar proteinosis

- Congenital pulmonary alveolar proteinosis is a rare cause of immediate onset of neonatal respiratory distress.
- Non-specific opacity on chest x-ray.
- Precipitate may be focal to confluent.
- Histopathology:
- Homogenous amorphous protein-lipid granular precipitate found in alveoli.
- Alveolar walls are not remarkable.
- Whole lung lavage to remove precipitate.
- GM-CSF administration useful in a majority of cases.

Pulmonary alveolar proteinosis

- Abnormalities found in congenital cases:
- ATP-binding cassette protein (ABAC3)
- Involved in transport of surfactant components in the lamellar body membrane
- Surfactant proteins B and C (SP-B, SP-C) deficient
- Autosomal recessive
- GM-CSF and GM receptor (GM-CSF/IL-3/IL-5 receptor)
- Antibodies to GM-CSF found in acquired disease.
- Deficiency of GM-CSF associated with impaired surfactant clearance.

ASTHMA

Asthma

- Peak age of 3 years.
- Boys 2:1
- Many with asthma become asymptomatic during adolescence but that asthma returns in some during adult life, particularly in those with persistent symptoms and severe asthma.
- Equal sex involvement by adulthood
- Adults with asthma, including those with onset during adulthood, rarely become permanently asymptomatic.
- Severity of asthma does not vary within a patient

Asthma

- Episodic or chronic symptoms of wheezing, dyspnea at rest, or chronic non-productive cough.
- Symptoms may be worse, or only present at night, due to the physiologic drop in cortisol secretion, airway cooling, decreased mucociliary clearance, and low levels of endogenous catecholamines.
- Ciliary dyskinesia and increased mucus production are also seen in asthma.
- Exacerbations frequently related to viral infection.

Asthma

- Prolonged expiration or wheeze on physical examination at rest is compatible with airway obstruction.
- A wheeze may be present with forced expiration in normal patients
- If airflow severely limited, there may be not wheeze
- Limitation of airflow on pulmonary function testing or positive bronchoprovocation challenge.
- Reversibility of airflow obstruction, either spontaneously or following bronchodilator therapy.

Critical asthma syndrome

- Tachycardia and tachypnea
- Blood pressure dependent upon adrenergic tone, fluid status, and respiratory effects on cardiac output
- Impending respiratory failure includes the inability to speak, the use of accessory muscles, the need to keep an upright posture, paradoxical chest and abdominal breathing pattern, minimal wheezing, and worsening fatigue.
- Respiratory failure includes lethargy, cyanosis, reduced air movement, and lack of wheezing.
- Pulsus paradoxus indicates potential severe hyperinflation and extracardiac tamponade

Critical asthma syndrome

- If on ventilator
- Low minute ventilation
- Oxygen requirements > 30%-50% fractional percent should prompt evaluation for complications such as pneumothorax or pneumonia.
- Short acting bronchodilators and corticosteroids (as with non-critical patients)



Representative spirograms (upper panel) and expiratory flow-volume curves (lower panel) for normal (A), obstructive (B), and restrictive (C) patterns.

TABLE 281-1

Risk Factors and Triggers Involved in Asthma

ENDOGENOUS FACTORS	ENVIRONMENTAL FACTORS
Genetic predisposition	Indoor allergens
Atopy	Outdoor allergens
Airway hyperresponsiveness	Occupational sensitizers
Gender	Passive smoking
Ethnicity	Respiratory infections
Obesity	Air pollution (diesel particulates, nitrogen oxides)
Early viral infections	Diet
	Dampness and mold exposure
	Acetaminophen (paracetamol)
Triggers	
Allergens	
Upper respiratory tract viral infections	
Exercise and hyperventilation	
Cold air	
Sulfur dioxide and irritant gases	
Drugs (β-blockers, aspirin)	
Stress	
Irritants (household sprays, paint fumes)	

Atopic asthma

- Nasal mucosal swelling, increased secretions, and polyps are often seen in patients with allergic asthma.
- Eczema, atopic dermatitis, or other allergic skin disorders may also be present
- Allergens that lead to sensitization have protease activity
- A type I hypersensitivity reaction involving CD4 T_{H2} cells, which release IL-4 and IL-5.
- IL-4 and IL-5 stimulate eosinophils and production of IgE.
- Family history of allergies.

Non-atopic asthma

- Asthma in patients with no family history of allergies and who have normal levels of IgE.
- Non-atopic individuals have low risk of developing asthma
- 10%, non-atopic or intrinsic asthma, usually show adult-onset asthma, commonly have concomitant nasal polyps, and may be aspirin-sensitive.
- Usually have more severe, persistent asthma.

Non-atopic asthma

- Staphyloccal superantigens may promote local IgE production in non-atopic asthma.
- T_{H2} innate lymphoid cells (ILC2) may drive the eosinophilic inflammation in these non-allergic patients.
- Exposure to infections and endotoxin results in a shift toward a predominant protective T_{H1} immune response (Hygiene hypothesis)

Asthma

- Risk factors:
- Obesity (BMI >30 kg/m^2)
- Particularly women
- Exercise
- GERD
- Cold air (increased air density)
- Viral infection
- Rhinovirus, parainfluenza virus

Asthma

- Susceptibility locus on chromosome 5q.
- Gene cluster encoding IL-3, IL-4, IL-5, IL-9, IL-13; IL-4R, LPS receptor (CD14), and β-adrenergic receptor map to 5q susceptibility locus.
- IL-5 critical in eosinophil regulation.
- IL-13 critical in mucus production
- CD14 TT genotype protective against low levels of endotoxin exposure
- Associated with asthma or allergic sensitization with high levels of endotoxin exposure.

Asthma

- Limitation of airflow is due mainly to bronchoconstriction (from mast cell mediators)
- Early closure of peripheral airway results in lung hyperinflation (air trapping) and increased residual volume
- Ventilation-perfusion mismatching in severe disease
- Respiratory failure uncommon
- Wheezing (positive likelihood ratio, LR+, 5.8; LR-, 0.3), dyspnea at rest (LR+, 9.2; LR-, 0.6), and nocturnal dyspnea (LR+, 11.5; LR-, 0.6) predictive of asthma

Components of Severity		Classification of Asthma Severity ≥ 12 years of age			
			Persistent		
		Intermittent	Mild	Moderate	Severe
Impairment	Symptoms	≤ 2 days/week	> 2 days/week but not daily	Daily	Throughout the day
	Nighttime awakenings	≤ 2x/month	3–4x/month	> 1x/week but not nightly	Often 7x/week
	Short-acting β_2-agonist use for symptom control (not prevention of EIB)	≤ 2 days/week	> 2 days/week but not daily, and not more than 1x on any day	Daily	Several times per day
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited
Normal FEV_1/FVC: 8–19 yr 85%; 20–39 yr 80%; 40–59 yr 75%; 60–80 yr 70%	Lung function	• Normal FEV_1 between exacerbations • FEV_1 > 80% predicted • FEV_1/FVC normal	• FEV_1 > 80% predicted • FEV_1/FVC normal	• FEV_1 > 60% but < 80% predicted • FEV_1/FVC reduced 5%	• FEV_1 < 60% predicted • FEV_1/FVC reduced > 5%
Risk	Exacerbations requiring oral systemic corticosteroids	0–1/year (see note)	≥ 2/year (see note)		
		Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time for patients in any severity category. Relative annual risk of exacerbations may be related to FEV_1.			
Recommended Step for Initiating Treatment		Step 1	Step 2	Step 3 and consider short course of oral systemic corticosteroids	Step 4 or 5
(See Figure 9-2 for treatment steps.)		In 2–6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.			

EIB, exercise-induced bronchospasm; FEV_1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICU, intensive care unit.

Asthma

- ADAM-33 (metalloproteinase) polymorphisms associated with accelerated proliferation of bronchial smooth muscle cells and fibrosis.
- Chitin is a polysaccharide present in many human parasites and in the cell walls of fungi.
- Acidic mammalian chitinase upregulated in asthma; contributes to T_{H2} inflammation.
- Mamamalian chitinase YKL-40 correlated with asthma severity.

Asthma

- Early stage of asthma:
- Reflex stretching of smooth muscle in bronchial walls leads to intracellular Ca^{2+} release and increased tension.
- This leads to release of mediators from cells
- Leukotrienes C_4, D_4, and E_4 promote bronchoconstriction
- Mast cell tryptase
- Inactivates vasoactive intestinal peptide (VIP)
- Edema and increased vascular permeability.

Asthma

- Histamine, prostaglandin D_2, and platelet activating factor appear to play minor roles.
- Acetylcholine is released from intrapulmonary motor nerves
- Directly stimulating muscarinic receptors
- Bronchoconstriction.

Asthma

- Late stage of asthma:
- Due to release of enzymes by eosinophils and neutrophils:
- Leukotrienes C_4, D_4, E_4
- The arrival of eosinophils and neutrophils is induced by chemotactic factors released during the early stage of asthma.
- Neutrophils release proteases, and eosinophils release major basic protein, which are directly toxic to epithelial cells.
- The late phase is responsible for the morphologic changes that occur in asthma.





Asthma

- Low peak expiratory flow rate (PEFR).
- PEFR lowest in the morning and highest at mid-day.
- In mild persistent asthma, PEFR >80% predicted.
- In severe persistent asthma, PEFR <60% predicted.
- FEV_1/FVC is often decreased as in other obstructive lung diseases, and residual volume is increased.
- Methacholine produces decrease of >20%; bronchodilators increase >12%.
- Low pCO_2 (hyperventilation).
- Rising pCO_2 presages respiratory failure.

Histopathology

- Gross:
- Lungs are hyperinflated.
- May see mucus plugs in bronchioles.
- Histopathology:
- Basement membrane is thickened due to subepithelial fibrosis with deposition of types III and V collagen below the true basement membrane
- Is associated with eosinophil infiltration
- Smooth muscle hypertrophy
- β-receptors uncoupled
- Mucous gland hyperplasia
- Eosinophilic infiltrate

Histopathology

- Desquamated epithelial casts in mucus (Curschmann spirals)
- Bronchial columnar cells in mucus (Creola bodies)
- Charcot-Leyden crystals
- Major basic protein or eosinophil lysophospholipase binding protein, galectin-10

Bronchial cast

Cast of the bronchial tree is formed of inspissated mucus

https://webpath.med.utah.edu/LUNGHTML/LUNG051.html
Accessed 01/10/2020

Sputum



Left: Curschmann spiral

Right: Charcot-Leyden crystal

https://en.wikipedia.org/wiki/Curschmann's_spirals#/media/File:Curshman's_Spiral.jpg
https://en.wikipedia.org/wiki/Charcot%E2%80%93Leyden_crystals#/media/File:Charcot-Leyden_crystals,_HE_1.jpg
Accessed 02/20/2020

Asthma



Fig. 19-42 Accessed 04/27/2010

A section through a primary bronchus is shown.

A plate of cartilage (arrow) identifies this as a bronchus.

The wall is thickened as a result of smooth muscle hypertrophy, and there is also an infiltrate of inflammatory cells (arrowhead).

Asthma



The numerous eosinophils are prominent from their bright red cytoplasmic granules

https://webpath.med.utah.edu/LUNGHTML/LUNG183.html
Accessed 01/10/2020



Source: J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo: Harrison's Principles of Internal Medicine, 20th Edition

Box 7A. The GINA asthma treatment strategy – adults and adolescents



ICS: inhaled corticosteroid; LABA: long-acting beta$_2$-agonist; LAMA: long-acting muscarinic antagonist; LTRA: leukotriene receptor antagonist; OCS: oral corticosteroid; SABA: short-acting beta$_2$-agonist

See Box 8A (p.26) for children 6–11 years. For more details about treatment recommendations, and for supporting evidence, and clinical advice about implementation in different populations see the full GINA 2021 report (www.ginasthma.org). For more details about Step 5 add-on therapies, see Chapter 3E of the GINA report or the GINA 2021 Pocket Guide on Difficult to Treat and Severe Asthma, and check eligibility criteria with local payers.

Box 7B. Initial treatment: adult or adolescents with a diagnosis of asthma



ICS: inhaled corticosteroid; SABA: short-acting beta$_2$-agonist

For initial asthma treatment in children 6–11 years, see Box 8B (p.28). For more details about treatment recommendations including supporting evidence, and clinical advice about implementation in different populations see the full GINA 2021 report (www.ginasthma.org). For more details about Step 5 add-on therapies, see Chapter 3E of the GINA report, or the GINA 2021 Pocket Guide on Difficult to Treat and Severe Asthma, and check eligibility criteria with local payers.

Box 8A. The GINA asthma treatment strategy – children 6–11 years



ICS: inhaled corticosteroid; LABA: long-acting beta$_2$-agonist; LTRA: leukotriene receptor antagonist; OCS: oral corticosteroid; SABA: short-acting beta$_2$-agonist.
See Box 7A (p.22) for adults and adolescents. For more details about treatment recommendations, and for supporting evidence, and clinical advice about implementation in different populations see the full GINA 2021 report (www.ginasthma.org). Check eligibility criteria with local payers.

Box 8B. Initial treatment: children 6–11 years with a diagnosis of asthma



ICS: inhaled corticosteroid; LABA: long-acting beta$_2$-agonist; LTRA: leukotriene receptor antagonist; OCS: oral corticosteroid; SABA: short-acting beta$_2$-agonist.
For initial asthma treatment in adults and adolescents, see Box 7B (p.24). For more details about treatment recommendations including supporting evidence, and clinical advice about implementation in different populations see the full GINA 2021 report (www.ginasthma.org). Check eligibility criteria with local payers.

Asthma therapy

- Inhaled corticosteroids with inhaled long acting β-agonist (Budenoside/formoterol)
- Short acting β-agonist increases risk of allergic responses, airway inflammation, and severe exacerbations.
- 15-20% die if monotherapy alone
- A short course of systemic steroids for acute episodes (reduce inflammation).
- Add-on treatments include long acting muscarinic agents (ipatropium)
- If exhaled Nitric Oxide is >25 ppb, consider biologic therapy (anti-IgE, anti-IL4R, anti-IL5R and anti-IL5)

Asthma therapy

- Add-on treatments include long acting muscarinic agents (ipatropium)
- Increases acetylcholine release, blocking bronchoconstriction.
- Use if history of smoking history
- If exhaled Nitric Oxide is >25 ppb, consider biologic therapy (anti-IgE, anti-IL4R, anti-IL5R and anti-IL5)

Asthma therapy

- Azithromycin reduces exacerbations
- Cromolyn prevents release of mediators from mast cells and alters function of delayed chloride channels.
- Possibly useful for prophylaxis.
- Phosphodiesterase inhibitors (theophylline) rarely required
- Yearly infusion of zoledronic acid to retard development of osteoporosis for those on steroids.

Asthma therapy

- Admit patient if peak flow rate is less than 60L/min or does not improve to >50% of predicted value after 1 hour of treatment.
- FEV_1 should improve by 10-15% in response to a bronchodilator.
- Increased p_aCO_2 indicates respiratory failure and should prompt admission.



ED, emergency department; MDI, metered-dose inhaler; PEF, peak expiratory flow; SABA short-acting beta-2-agonist (quick-relief inhaler).



FEV_1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; MDI, metered-dose inhaler; PEF, peak expiratory flow; SABA, short-acting beta-2-agonist; SaO_2, oxygen saturation.

Paroxysmal vocal cord movement

- Young women principally.
- Episodic adduction of the vocal cords producing wheezing and stridor.
- May be confused with asthma. Hoarseness and lack of response to bronchodilators are diagnostic clues.
- Normal spirometry.
- Bronchoprovocation tests are normal.
- Diagnosed by laryngoscopy.

Paroxysmal vocal cord movement

- Speech therapy, concentrating on laryngeal exacerbation is most effective therapy.
- Breathing through pursed lips with the tongue on the floor of the mouth is useful in the acute situation.

CHRONIC BRONCHITIS

Atelectasis

- Atelectasis is collapse of the pulmonary parenchyma with resorption of trapped air by blood in pulmonary capillary
- Collapsed lung does not expand on inspiration
- Usually caused by mucopurulent plug following surgery
- Fever generally present within 24 hours.
- Loss of breath sounds and fremitus
- If volume of lung involved is large, may see dyspnea.

Atelectasis

- Aspiration or bronchogenic carcinoma as other causes of airway obstruction
- Tension pneumothorax or large pleural effusion may compress subpleural alveoli and collapse themGas exchange is impaired in the involved lung
- Perfusion without ventilation
- Increased Alveolar-arterial gradient

Atelectasis

- If the atelectasis is due to airway obstruction (e.g., mucus, foreign body, tumor), the mediastinum shifts towards the source of the atelectasis.
- Endoscopy with clearance of the obstruction may allow the lung to re-expand
- Routinely post-surgery, lung expansion exercises are undertaken
- If the atelectasis is due to external compression (eg., pleural fluid, blood, or air), the mediastinum shifts away from the source of the atelectasis.
- External fluid or gas must be drained to permit the lung to re-expand

Acute bronchitis

- Presents in the healthy adult as a (low volume) productive cough for 1-3 weeks with myalgias and low grade fever.
- Cough as a result of bronchial hyper-responsiveness. Sputum may be clear.
- Rarely bacterial
- Bordatella pertussis, Mycoplasma pneumoniae, Chlamydiae comon
- Antibiotics of no benefit.
- Antitussives and bronchodilators may offer symptomatic relief.

Chronic bronchitis

- Chronic productive cough for most days of the month, 3 months of the year, for 2 successive years.
- Patients referred to as "blue bloaters" as are hypercapnic
- CO_2 cannot be expelled as airway obstructed but is absorbed in capillary blood
- Hypoxemia early in course of disease
- Bluing (cyanosis) of mucous membranes
- Use accessory muscles to breathe.
- Expiratory wheezing and sibilant rhonchi
- Respiratory acidosis
- Obstruction by mucus plugs may lead to atelectasis or bronchiectasis.

Chronic bronchitis

- Frequently develop secondary pulmonary hypertension and right heart failure (core pulmonale)
- WHO/NHLBI guidelines based on post-bronchodilator spirometry:
- Moderate COPD associated with FEV_1 of 50-80%
- Severe COPD associated with FEV_1 of 30-50%
- Histopathology:
- Mucus gland hyperplasia.
- Chronic inflammation.

Chronic bronchitis

- Dullness to percussion along left lower sternal border (cardiac silhouette) has a positive likelihood ratio (LR+) of 15 for the diagnosis of COPD.
- A sub-xiphoid cardiac impulse has an LR+ of 8.
- Upper lobe bullous disease, while uncommon, is diagnostic
- Arterial blood gas measurement necessary in patients with FEV_1 <40% or with right heart failure.
- If the calculated pH (7.66 – 0.0092 pO_2) is greater than the true pH, the patient is at high risk for intubation.
- Oxygen should not be withheld.

Chronic bronchitis



The bronchus has increased numbers of chronic inflammatory cells in the submucosa.

https://webpath.med.utah.edu/LUNGHTML/LUNG055.html
Accessed 01/10/2020

Bronchiectasis

- Dyspnea and chronic purulent sputum production usually present.
- Hemoptysis is common.
- Irreversible consequence of continued inflammation (and ciliary dyskinesia) with fibrosis
- Small-airway wall inflammation and larger-airway wall destruction as well as dilation, with loss of elastin, smooth muscle, and cartilage

Bronchiectasis

- Focal bronchiectasis
- A consequence of obstruction of the airway
- Extrinsic, due to compression by adjacent lymphadenopathy or parenchymal tumor mass
- Intrinsic, due to an airway tumor or aspirated foreign body, a scarred/stenotic airway, or bronchial atresia from congenital underdevelopment of the airway.
- Diffuse bronchiectasis
- Characterized by widespread changes throughout the lung
- Often arises from an underlying systemic or infectious disease process.

Bronchiectasis

- Cystic fibrosis is the most common cause in the US
- Bordatella pertussis and Mycobacterium tuberculosis once were common causes.
- In the post-antibiotic era, causes are often viral
- Lymphadenopathy causing airway obstruction
- Hemophilus influenzae, Pseudomonas aeruginosae, and Streptococcus pneumonia are the usual bacterial organisms isolated.

Bronchiectasis

- Involvement of the upper lung fields is most common in cystic fibrosis (CF)
- Bronchiectasis with predominant involvement of the lower lung fields usually has its source in chronic recurrent aspiration
- Mycobacterium avium-intracellulare complex (MAC), often preferentially affects the midlung fields.
- Congenital causes of bronchiectasis with predominant midlung field involvement include the dyskinetic/immotile cilia syndrome
- Central airways involved with ABPA (Aspergillus species)

Bronchiectasis

- CT scan will show diagnostic airway changes.
- Dilated medium sized airways extend to periphery
- Tubular or saccular
- Surgery only to treat airway obstruction or remove necrotic tissues.



Representative chest CT image of severe bronchiectasis. This patient's CT demonstrates many severely dilated airways, seen both longitudinally (arrowhead) and in cross-section (arrow).

Kartagener's syndrome

- Primary ciliary dyskinesia
- Missing dynein arm of cilium
- Loss of ATPase (energy to move cilia is lost)
- Impairs airway clearance
- Associated with:
- Sinusitis
- Otitis media
- Bronchiectasis
- Infertility
- Situs inversus (in 50%)

Bronchiectasis

Dilated bronchi are present in the mid lower portion of the lung, and extend to the pleura

https://webpath.med.utah.edu/LUNGHTML/LUNG053.html.
Accessed 01/10/2020

Bronchiectasis



The bronchus has residual epithelium with necrotizing inflammation with subsequent bronchial destruction, and inflammation extending into the adjacent lung parenchyma.

https://webpath.med.utah.edu/LUNGHTML/LUNG054.html
Accessed 01/10/2020

COPD

Chronic obstructive lung disease

- COPD is a disease of the lungs that impairs the ability of air to leave the alveoli during expiration, trapping it.
- Airflow limitation is not fully reversible
- Clinically defined by the decreased FEV_1/FVC ratio.
- The residual volume and functional residual capacity (FRC) are increased, but the total lung capacity may remain normal.
- The condition eventually leads to hypercapnic respiratory failure.
- Pulmonary vagal activity is increased.

COPD

- Emphysema
- Anatomically defined
- Characterized by destruction of the lung alveoli with air space enlargement
- Chronic bronchitis
- Clinically defined
- Characterized by chronic cough and phlegm
- Small airway disease
- Characterized by narrow small bronchioles that are also reduced in number

Chronic obstructive lung disease

- Cough, sputum production, and exertional dyspnea are the common presenting signs
- Emphysema, chronic bronchitis, and small airway disease are present in varying degrees
- Patients with a history of cigarette smoking without chronic airflow obstruction may have chronic bronchitis, emphysema, and dyspnea.
- COPD is the second leading indication for lung transplantation

COPD

- PaO_2 usually remains near normal until the FEV_1 is decreased to <50% of predicted
- Much lower FEV_1 values can be associated with a normal PaO_2 at rest.
- An elevation of arterial level of carbon dioxide ($PaCO_2$) is not expected until the FEV_1 is <25% of predicted
- Then, at risk for pulmonary hypertension and right heart failure (Cor pulmonale)
- Non-uniform ventilation and ventilation-perfusion mismatching are characteristic of COPD
- Accounts for the reduction in PaO_2

Emphysema

- Chest X-ray:
- Flattened diaphragms
- Lung fields are hyperlucent.
- EKG:
- Small amplitude QRS (due to increased airspace)
- Right axis deviation (usually associated with right ventricular hypertrophy).

COPD

- Chest computed tomography (CT) scan is the current definitive test for establishing:
- The presence or absence of emphysema
- The pattern of emphysema
- The presence of significant disease involving medium and large airways

Testing

- A barrel chest or wheezing in a child predicts airflow limitation.
- A smoking history >40 pack years with wheezing predicts airflow limitation (positive likelihood ratio, LR+, 159)
- Test all patients with COPD as well as those with asthma and airway obstruction for α_1-antitrypsin deficiency.

Emphysema

- Historically are referred to as “pink puffers” as hyperventilate to maintain oxygenation.
- Dyspnea and hyperventilation
- Hypoxemia and hypercapnia,
- Decreased breath sounds and increased expiratory phase on auscultation.
- Tachycardia is common.
- Multifocal atrial tachycardia is classic.
- Pursed lips to maintain airways open in expiration
- Chronic respiratory acidosis with compensatory alkalosis in stable patients.

Pathogenesis

- Cigarette smoke exposure may affect the large airways, small airways (≤2 mm diameter), and alveoli.
- Changes in large airways cause cough and sputum production, while changes in small airways and alveoli are responsible for physiologic alterations.
- Airway inflammation, destruction, and the development of emphysema are present in most persons with COPD
- Appear to be relatively independent processes
- <u>The early development of chronic airflow obstruction is driven by small airway disease</u>

Pathogenesis

- The inhalations of allergens stimulate sensory nerve endings (irritant receptors) lying below the airway epithelium.
- Stimulation of these irritant receptors causes parasympathetic nerves to release acetylcholine (ACh).
- When acetylcholine binds to M3 muscarinic receptors on airway smooth muscle, a series of events is initiated which results in an increase in intracellular calcium (Ca^{++}) and smooth muscle contraction (bronchoconstriction or bronchospasm).

Pathogenesis of emphysema



Breathing mechanics

- Loss of pulmonary parenchyma with enlargement of alveolar spaces.
- The loss of pulmonary parenchyma causes a loss of elastic recoil.
- Elastic tissue applies radial traction to keep airways open.
- When the patient breathes out, the airways collapse, trapping air because of reduced driving pressure.
- $D_{L_{CO}}$ diminished.

Breathing mechanics

- Hyperinflation decreases the zone of apposition between the diaphragm and the abdominal wall
- Positive abdominal pressure during inspiration is not applied as effectively to the chest wall
- Hinders rib cage movement and impairs inspiration.
- The thoracic cage is distended beyond its normal resting volume
- During tidal breathing the inspiratory muscles must do work to overcome the resistance of the thoracic cage to further inflation

Breathing mechanics

- Muscle fibers of the flattened diaphragm are shorter than those of a more normally curved diaphragm
- Less capable of generating inspiratory pressures
- The flattened diaphragm must generate greater tension to develop the transpulmonary pressure required to produce tidal breathing.

Histopathology

- Mucus gland enlargement and goblet cell hyperplasia throughout bronchial tree
- Mucus-secreting cells replacing surfactant-secreting Club cells.
- Reduced surfactant may increase surface tension at the air-tissue interface, predisposing to airway narrowing or collapse
- Smooth-muscle hypertrophy and bronchial hyper-reactivity leading to airflow limitation.
- Neutrophil elastase potent attractor of neutrophils

Histopathology

- Large airways:
- Mucosa may undergo squamous metaplasia
- Small airways
- Luminal narrowing can occur by fibrosis, excess mucus, edema, and cellular infiltration.
- Mononuclear peribronchial inflammatory infiltrate
- Narrowing and drop-out of small airways
- The walls of respiratory bronchioles, alveolar ducts, and alveoli become perforated and later obliterated
- Coalescence of the delicate alveolar structure into large emphysematous air spaces.
- Large numbers of macrophages accumulate



Evolution of emphysema

There is an increase in the number and size of pores of Kohn, resulting in vulnerability of the alveoli.

The framework structure and alveoli merge and break down because of mechanical stress and/or inflammation, inducing traction of lung tissue and remodeling of acini, resulting in enlarged air spaces of emphysema

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033613/figure/f2-copd-11-2287/

Accessed 01/10/2020

Emphsyema



Loss of alveolar walls with emphysema is demonstrated. Remaining airspaces are dilated.

https://webpath.med.utah.edu/LUNGHTML/LUNG059.html
Accessed 01/10/2020

Centrilobular emphysema

- Associated with cigarette smoking
- Characterized by enlarged air spaces found (initially) in association with respiratory bronchioles.
- Most prominent in the upper lobes and superior segments of lower lobes and is often quite focal.
- May see subpleural bullae.

Centrilobular emphysema

- The central or proximal parts of the acini, formed by respiratory bronchioles, are affected.
- Distal alveoli are spared.
- Both emphysematous and normal airspaces exist within the same acinus and lobule.
- Inactivation of anti-proteases, increased elastase production by inflammatory cells, and reactive Oxygen species contribute to alveolar damage.

Paraseptal emphysema

- 10–15% of cases
- Distributed along the pleural margins, along the lobular connective tissue septa, and at the margins of lobules.
- Relative sparing of the lung core or central regions.
- Only the distal acinus is involved.
- May occur adjacent to inflammation or fibrosis
- More marked in upper lobes.
- It is commonly associated with significant airway inflammation and with centrilobular emphysema.
- Spontaneous pneumothorax common.

Emphysema



Increased lucency, flattened diaphragms (black arrows), increased AP diameter, and increased retrosternal clear space (red arrow)

Fig. e24-8 Accessed 03/17/2010

Centrilobular emphysema



Dilated airspaces with emphysema are seen.

https://webpath.med.utah.edu/LUNGHTML/LUNG057.html
Accessed 01/10/2020

Centrilobular emphysema

Where the central portions of lung acini have lost lung parenchyma, focal holes are noted. Anthracotic pigment collected. Typical of smokers.

https://webpath.med.utah.edu/LUNGHTML/LUNG058.html
Accessed 01/10/2020

Centrilobular emphysema



Source: Wilson FJ, Kestenbaum MG, Gibney JA, Matta S: *Histology Image Review*: http://www.accessmedicine.com

Fig 19-41 Accessed 04/27/2010

Enlarged alveolar sacs and alveoli are illustrated.

The interstitial area exhibits an increase in collagenous tissue (arrow).

The interalveolar septum is fibrotic and the airways (arrowhead) are markedly dilated.

Paraseptal
Distal acinar emphysema

Subpleural airspaces with smooth wall structures.

Fixed inflated lung.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629965/figure/f22-copd-3-193/
Accessed 01/10/2020

Tobacco

- Exposure of children to maternal smoking results in significantly reduced lung growth.
- In utero, tobacco smoke exposure also contributes to significant reductions in postnatal pulmonary function.
- Increases risk of Sudden Infant Distress Syndrome and Cleft Palate
- Although passive smoke exposure has been associated with reductions in pulmonary function, its contribution is unknown.

Tobacco

- Breastfed infants of mothers who smoke or use snuff are exposed to nicotine in breast milk
- Altered brain development as a result of fetal hypoxia
- Nicotine disrupts brain development via cholinergic mechanisms.
- Affects hindbrain, hippocampus, and sensorimotor cortex
- Accelerates atherosclerosis
- Increases resting sympathetic activity

Effects of inhaled nicotine

- Nicotine is a chemo-attractant of neutrophils by induction of nuclear factor-κB (NF-κB)
- Results in production of tumor necrosis factor (TNF) and interleukin-8 (IL-8).
- TNF and IL-8 activate neutrophils, leading to expression of adhesion molecules.
- Neutrophils release damaging proteases (e.g., elastase).
- α1-antitrypsin protective
- Nicotine causes production of reactive oxygen species which deplete antioxidants.

Chemical carcinogenesis

- Carcinogens in tobacco smoke are benzo [a] pyrene (an initiator) and phenol derivatives (promoters)
- CYP1A1 is a cytochrome P450 enzyme that metabolizes polyaromatic hydrocarbons through hydroxylation of vacant position on aromatic ring
- Mediated via aryl hydrocarbon receptor
- CYP1A1 gene at 15q24.1
- 10% of whites have a highly inducible form
- Light smokers 7x more likely to develop lung cancer than those without this genotype



Source: J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo: Harrison's Principles of Internal Medicine, 20th Edition



Source: J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo: Harrison's Principles of Internal Medicine, 20th Edition

Impact of smoking cessation on COPD

- From age 20 to 45, there is little decline in FEV_1 in those who have never smoked.
- Then begins a gradual decline in FEV_1 to 55% of the age 20 baseline by age 90.
- A smoker at age 20 begins to show a rapid decline in FEV_1 to 70% of baseline at 45 years of age.
- Should the smoker cease at that time, the decline is more gradual, reaching 35% of baseline at age 90.

Impact of smoking cessation on COPD

- Symptoms generally appear at 50% of baseline FEV_1, with disability noted at 35%.
- If the smoker does not cease until age 55, FEV_1 at that point is 40% of baseline.
- It is rare that such a smoker survives to reach 80 years of age.

Panacinar emphysema

- Initial distention of the alveolus and alveolar duct.
- The disease later extends to affect the respiratory bronchioles.
- The disease begins distally and moves centrally.
- The entire acinus is involved.
- Involves the entire lung, particularly the bases.
- Associated with α_1-antitrypsin deficiency.
- α_1-antitrypsin inactivates circulating trypsin
- SERPIN A gene
- Older nomenclature: PiMM normal genotype
- Older nomenclature: PiZZ liver cannot secrete α_1-antitrypsin

Panacinar emphysema



Multiple large bullae bilateralllly. Note both upper and lower lobe hyperlucency.

https://images.radiopaedia.org/images/449024/1b69a65774aa3c48d2292f98b50728_jumbo.jpeg
Accessed 01/10/2020

Panacinar emphysema

Enlargements of airspaces are diffusely observed and in some areas the disease is bordered by the interlobular septum (arrow).

Fixed inflated specimen.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629965/figure/f18-copd-3-193/
Accessed 01/10/2020



CT patterns of emphysema. A. Centrilobular emphysema with severe upper lobe involvement in a 68-year-old man with a 70 pack-year smoking history but forced expiratory volume (FEV_1) 81% predicted (GOLD spirometry grade 1); B. Panlobular emphysema with diffuse loss of lung parenchymal detail predominantly in the lower lobes in a 64-year-old man with severe α_1AT deficiency; and C. Paraseptal emphysema with marked airway inflammation in a 52-year-old woman with a 37 pack-year smoking history and FEV_1 40% predicted.

Chronic pulmonary fibrosis with emphysema

- Coexistence of interstitial fibrosis and emphysema
- Centrilobular emphysema in upper lobes
- Usual interstitial pneumonia in lower lobes
- Cause of interstitial fibrosis associated with outcome
- Pulmonary hypertension poor prognostic sign
- Obstructive pattern on pulmonary function tests
- $D_{L_{CO}}$ reduced disproportionately
- 98%, smokers
- High resolution CT diagnosis
- Nintedanib slows FVC decline
- Increased risk of carcinoma

Chronic pulmonary fibrosis with emphysema



Top row is from upper lung areas showing emphysematous cystic spaces along with brown, normal-appearing area, while lower lung areas showed honeycomb changes. Arrowheads indicate pulmonary adenocarcinoma showing well circumscribed white, solid mass without remarkable necrosis.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501445/figure/f2-copd-10-1299/
Accessed 01/10/2020

GOLD Criteria for Severity of Airflow Obstruction in COPD

GOLD Stage	Severity	Spirometry
I	Mild	$FEV_1/FVC < 0.7$ and $FEV_1 \geq 80\%$ predicted
II	Moderate	$FEV_1/FVC < 0.7$ and $FEV_1 \geq 50\%$ but $< 80\%$ predicted
III	Severe	$FEV_1/FVC < 0.7$ and $FEV_1 \geq 30\%$ but $< 50\%$ predicted
IV	Very severe	$FEV_1/FVC < 0.7$ and $FEV_1 < 30\%$ predicted

http://www.goldcopd.org

Modified Medical Research Council Dyspnea Scale.

- mMRC provides a single number for degree of breathlessness:
- 0 only with strenuous activity
- 1 hurrying on level ground or walking up a slight hill
- 2 walk slower than peers or stop walking at their own pace
- 3 walking about 100 yards or after a few minutes on level ground
- 4 too breathless to leave the house or when dressing.



Source: J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo: Harrison's Principles of Internal Medicine, 20th Edition

COPD therapy

- Inhaled short acting β-agonist or inhaled muscarinic antagonist as needed for intermittent symptoms (cough, wheeze, exertional dyspnea).
- Inhaled long acting β-agonist for persistent symptoms (particularly night wakening).
- Add inhaled corticosteroids if no relief.
- Supplemental O_2 is indicated for those who do not retain CO_2 if the resting pO_2 is <55 mmHg or the S_{aO_2} is <88%.
- Else, may eliminate respiratory drive.
- Reduction in mortality

COPD therapy

- Noninvasive ventilation (NIV) in patients with acute COPD exacerbations with acute respiratory failure who do not require emergent intubation
- Contraindications include respiratory arrest, cardiovascular instability, copious secretions, high aspiration risk, inability to assess mental status due to hypercapnia, extreme obesity, thermal upper airway injury, and inability to properly fit a mask.
- The decision to intubate should take into account the likelihood of reversing the precipitating event
- Correct respiratory acidosis and hypoxemia while avoiding hyperinflation.



Source: J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo: Harrison's Principles of Internal Medicine, 20th Edition

http://www.goldcopd.org

COPD therapy

- Antibiotic therapy for acute infection (or exacerbation of chronic bronchitis).
- Subpleural blebs may have to be unroofed
- Lung reduction to permit expansion of functional lung
- FEV_1 50-80% 3 year mortality of 11%
- FEV_1 30-50% 3 year mortality of 15%
- FEV_1 <30% 3 year mortality of 24%

COPD therapy

- 50% of patients with respiratory distress were previously asymptomatic
- Hemoptysis requires bronchoscopy
- 1 cup full of blood lost in 24 hours is significant blood loss
- If stent placed, 3-7% hypertonic saline nebulizer to mobilize secretions
- Endobronchial placement of one-way valve (spiration, zephyr) to close bronchopleural fistula
- Endoscopic lung volume reduction prior to lung transplantation if total lung volume (TLC) >500ml

Pulmonary interstitial emphysema

- Air dissects through alveolar walls into the adjacent interstitial tissues
- Forms cystic spaces with an associated inflammatory reaction.
- Elongated or angulated spaces in fibrotic interstitium
- Most commonly around bronchovascular bundles
- Surrounded by dense fibrosis and lining of multiple giant cells, but not epithelium
- Associated with ventilator use
- Premature infants with respiratory distress syndrome
- Adult patients with usual interstitial pneumonia

Pneumothorax

- Acute onset pleuritic chest pain and dyspnea.
- Diminished breath sounds
- Hyper-resonance over area of collapse
- Decreased tactile fremitus.
- Usually subpleural apical bleb as cause.
- Common in COPD.
- May see in Marfan's syndrome (primary)
- May see in pneumocystis pneumonia.
- Thoracostomy for acute treatment.
- Pleurodesis if recurrent pneumothoraces.

Pneumothorax

Pleural reflection highlighted with *red arrows*.

Fig. e24-35 Accessed 03/17/2010

Subpleural bullae



Bullae are large dilated airspaces that bulge out from beneath the pleura.

May rupture and cause pneumothorax.

Emphysema is characterized by a loss of lung parenchyma by destruction of alveoli so that there is permanent dilation of airspaces with loss of elastic recoil.

https://webpath.med.utah.edu/LUNGHTML/LUNG056.html
Accessed 01/10/2020

Tension pneumothorax

- Presents with respiratory distress
- Worsens with each breath taken
- Tracheal deviation away from side of collapse
- Hypotension.
- Immediate thoracostomy as therapy.

CYSTIC FIBROSIS

Table 10-5 Clinical Features and Diagnostic Criteria for Cystic Fibrosis

Clinical Features of Cystic Fibrosis

1. *Chronic sinopulmonary disease manifested by*
   a. Persistent colonization/infection with typical cystic fibrosis pathogens, including *Staphylococcus aureus*, nontypeable *Haemophilus influenzae*, mucoid and nonmucoid *Pseudomonas aeruginosa, Burkholderia cepacia*
   b. Chronic cough and sputum production
   c. Persistent chest radiograph abnormalities (e.g., bronchiectasis, atelectasis, infiltrates, hyperinflation)
   d. Airway obstruction manifested by wheezing and air trapping
   e. Nasal polyps; radiographic or computed tomographic abnormalities of paranasal sinuses
   f. Digital clubbing
2. *Gastrointestinal and nutritional abnormalities, including*
   a. Intestinal: meconium ileus, distal intestinal obstruction syndrome, rectal prolapse
   b. Pancreatic: pancreatic insufficiency, recurrent acute pancreatitis, chronic pancreatitis
   c. Hepatic: chronic hepatic disease manifested by clinical or histologic evidence of focal biliary cirrhosis, or multilobular cirrhosis, prolonged neonatal jaundice
   d. Nutritional: failure to thrive (protein-calorie malnutrition), hypoproteinemia, edema, complications secondary to fat-soluble vitamin deficiency
3. *Salt-loss syndromes: acute salt depletion, chronic metabolic alkalosis*
4. *Male urogenital abnormalities resulting in obstructive azoospermia (congenital bilateral absence of vas deferens)*

Criteria for Diagnosis of Cystic Fibrosis

One or more characteristic phenotypic features,
   OR a history of cystic fibrosis in a sibling,
   OR a positive newborn screening test result
AND
An increased sweat chloride concentration on two or more occasions
   OR identification of two cystic fibrosis mutations,
   OR demonstration of abnormal epithelial nasal ion transport

Adapted with permission from Rosenstein BJ, Cutting GR: The diagnosis of cystic fibrosis: a consensus statement. J Pediatr 132:589, 1998.

Cystic fibrosis

- In US, screened for in neonates
- Some patients may not have symptoms until adolescence
- Disease largely found in those of Northern European ancestry.
- Heat exhaustion due to salt loss
- Chronic or recurrent productive cough, dyspnea, and wheezing
- May present in infancy with meconium ileus
- May present in early childhood with rectal prolapse

Cystic fibrosis

- Pulmonary problems
- 25%, nasal polyps
- Recurrent airway infections or chronic colonization of the airways with H influenzae, P aeruginosa, S aureus, Burkholderia cenocepacia, or Aspergilla
- 20%, pneumothorax
- Rupture of blebs that develop as a result of infection

Cystic fibrosis

- Gastrointestinal problems
- 85%, Pancreatic insufficiency
- Low concentrations of serum proteins
- Indicating protein malnutrition
- Drying and thickening of pancreatic secretions leads to
- Clogged pancreatic ducts
- Decreased digestion of dietary proteins and lipids.
- Foul-smelling, glistening, bulky stools.
- 20%, recurrent pancreatitis leading to diabetes mellitus

Cystic fibrosis

- 20%, Meconium ileus in newborn
- Rectal prolapse in infant
- 50%, Gallstones due to bile stasis
- 20% common duct obstruction
- Secondary biliary cirrhosis
- Genitourinary problems
- 90%, male infertility
- 20%, female infertility
- Urogenital abnormalities.

Cystic fibrosis

- Signs and symptoms:
- Parents may taste salt when kissing the child
- Slow growth rate.
- Often listless and irritable, tire easily.
- Difficult to clear airways.
- Repeated bouts of bronchitis.
- Thick, viscous secretions
- Bronchiectasis and scarring on chest radiographs
- Airway obstruction on spirometry

Cystic fibrosis

- Bacterial killing by neutrophils and β-defensins requires a normal chloride concentration.
- The chloride content of epithelial secretions is high in cystic fibrosis.
- Deficiency in mannose-binding lectin
- Important component of complement system
- Poor phagocytosis
- Increases the risk for pyogenic infections.
- Transforming growth factor-beta is a potent suppressor of T cell activation.

Molecular abnormality

- Mutation that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein at 7q31.2
- The CFTR protein belongs to the ABC (ATP-Binding Cassette) family of proteins.
- Gating of CFTR involves conformational cycling between an open and closed configuration
- Is augmented by hydrolysis of adenosine triphosphate (ATP).
- Anion flux mediated by CFTR does not involve active transport against a concentration gradient

Molecular abnormality

- Chloride and bicarbonate release is followed passively by the flow of water, allowing for mobilization and clearance of exocrine products.
- CFTR malfunction leads to
- Defective cAMP-dependent Cl^- secretion
- Increased Na^+ absorption
- Thickened, viscous secretions (dehydrated)
- Along respiratory mucosa, CFTR is necessary to provide sufficient depth of the periciliary fluid layer (PCL), allowing normal ciliary extension and mucociliary transport

Testing

- Hyperinflation is seen early in the disease process.
- Peribronchial cuffing, mucus plugging, bronchiectasis (ring shadows and cysts), increased interstitial markings, small rounded peripheral opacities, and focal atelectasis are common findings on chest x-ray.
- Pneumothorax can also be seen.
- Thin-section CT scanning often confirms the presence of bronchiectasis.
- The quantitative pilocarpine iontophoresis sweat test reveals elevated sodium and chloride levels

Diagnosis

- Sweat chloride concentration greater than 60 mEq/L on two occasions.
- >40 mEq/L in infants
- Presence of two (one from each parent) gene mutations known to cause cystic fibrosis.
- Abnormal nasal potential difference
- Increased immunoreactive serum trypsin levels

Treatment

- Postural drainage
- Inhalation of recombinant human DNAse to decrease sputum viscosity
- Cleaves extracellular DNA
- Inhalation of 7% saline solution
- Long term antibiotic therapy with azithromycin for those who have Pseudomonas aeruginosa in sputum culture
- Bronchodilator therapy as needed

Treatment

- Those with a ΔF508 mutation may benefit from a calcium channel potentiator (ivacaftor)
- Long-term survival now approaching 39 years
- Lung transplantation is definitive therapy for progressive disease (9 year survivals)



Figure 10-21 Lungs of a patient dying of cystic fibrosis. There is extensive mucus plugging and dilation of the tracheobronchial tree. The pulmonary parenchyma is consolidated by a combination of both secretions and pneumonia—the green color associated with *Pseudomonas* infections. (Courtesy Dr. Eduardo Yunis, Children's Hospital of Pittsburgh, Pittsburgh, Pa.)



Source: J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo: Harrison's Principles of Internal Medicine, 20th Edition



Figure 10-20 Pancreas in cystic fibrosis. The ducts are dilated and plugged with eosinophilic mucin, and the parenchymal glands are atrophic and replaced by fibrous tissue.

Bronchiectasis (cystic fibrosis)

Apical disease

Fig. e24-31 Accessed 03/17/2010

INTERSTITIAL LUNG DISEASE

Interstitial lung disease

- Interstitial lung disease is restrictive.
- Insidious onset of progressive dyspnea and nonproductive chronic cough
- Extrapulmonary findings may accompany specific diagnoses.
- Tachypnea
- Bibasilar dry rales
- Unable to complete a six minute walk
- Digital clubbing and right heart failure with advanced disease

Interstitial lung disease

- Reticulonodular pattern with diminished lung volumes noted on chest x-ray.
- Patchy distribution of ground glass or cystic opacities.
- TLC and FVC diminished
- FEV_1/FVC increased
- $D_{L_{CO}}$ diminished.
- Hypoxemia with exercise

Interstitial lung disease

- Other causes of restrictive lung expansion:
- Obesity and kyphoscoliosis impair lung filling by limiting chest expansion.
- Pleural fibrosis also impairs lung filling by limiting lung expansion.

Diagnostic clues

Radiographic finding	Diseases
Hilar adenopathy	Sarcoid, Lymphoma, Carcinoma, Granulomatous diseases
Pleural effusion	Vasculitis, lymphangiomyomatosis (chylous), asbestosis, TB
Pneumothorax	Eosinophilic Granuloma, PCP, lymphangiomyomatosis
Upper lung predominance	Silicosis, Sarcoid, Eosinophilic Granuloma
Peripheral predominance	Eosinophilic pneumonia, drug induced injury, IPF

Work-up

- Ask about occupation
- Ask about travel
- Ask about toxin exposure (including tobacco)
- Ask about medications (including herbs, OTC)
- Hypersensitivity pneumonitis
- Ask about family history
- Are there extra-pulmonary signs?
- Exclude congestive heart failure
- BNP elevated
- Chest x-ray and High resolution CT to evaluate disease process

Work-up

- Infection
- Viral
- Mycobacterial
- Fungal
- Atypical bacterial
- Parasitic
- Exclude malignancy
- Lymphangitic carinomatosis
- Lepidic adenocarcinoma

Acute restrictive lung disease

- Acute onset of respiratory distress and hypoxemia.
- Bilateral pulmonary infiltrates
- (1) Acute respiratory distress syndrome (ARDS)
- (2) Acute interstitial pneumonia (AIP, Hamman-Rich syndrome)
- Mechanism:
- Primary injury to the vascular endothelium
- Diffuse alveolar damage
- No evidence of left atrial hypertension
- Treatment is supportive

Acute restrictive lung disease

- ARDS may progress to multisystem organ failure.
- AIP Follows an acute upper respiratory infection
- 50% 6-month mortality rate
- Recurrences are common.
- Difficult to distinguish from exacerbations of interstitial lung disease

Acute restrictive lung disease

- Diminished $D_{L_{CO}}$
- FEV_1 and FVC diminished
- FEV_1/FVC ratio normal
- No obstructive component to movement of air
- HRCT:
- Patchy bilateral ground-glass opacities.
- Dependent regions of air-space consolidation

Table 294-1

Clinical Disorders Commonly Associated with ARDS

Direct Lung Injury	Indirect Lung Injury
Pneumonia	Sepsis
Aspiration of gastric contents	Severe trauma
Pulmonary contusion	Multiple bone fractures
Near-drowning	Flail chest
Toxic inhalation injury	Head trauma
	Burns
	Multiple transfusions
	Drug overdose
	Pancreatitis
	Postcardiopulmonary bypass

ARDS

- Causes include:
- 40%, Gram-negative sepsis
- 30%, Gastric aspiration
- 20%, Severe trauma with shock
- Pulmonary contusion
- Multiple bone fractures (fat embolism)
- Chest wall trauma/flail chest,

Diffuse alveolar damage

- NF-κB activation prominent.
- IL-8 synthesis increases within 30 minutes after insult.
- Chemotactic for neutrophils.
- Adhesion molecules upregulated.
- Coagulation system dysregulated.
- Tissue factor levels elevated while protein C levels are diminished.
- Capillary damage causes leakage of protein rich exudate into alveolar spaces





Source: J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo: Harrison's Principles of Internal Medicine, 20th Edition

Diffuse alveolar damage

- Histopathology:
- Some alveoli are collapsed while others are distended
- Many contain dense proteinaceous debris, desquamated cells, and hyaline membranes.
- Late findings include:
- Repair by Type II pneumocytes
- Progressive interstitial fibrosis

ARDS

- Pulmonary artery wedge pressure <18mmHg
- Elevated in cardiogenic pulmonary edema
- A-a gradient increased
- Ventilation-perfusion mismatch (atelectasis)
- Diffusion impaired (hyaline membranes)
- Chest x-ray shows bilateral interstitial infiltrates (as does cardiogenic pulmonary edema)
- May progress to widespread alveolar consolidation with air bronchogram

ARDS

- Mild ARDS
- Pa_{O2}/Fi_{O2} > 200 mm Hg but ≤ 300 mm Hg with positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) ≥ 5 cm H2O
- Moderate ARDS
- Pa_{O2}/Fi_{O2} > 100 mm Hg but ≤ 200 mm Hg with PEEP ≥ 5 cm H2O
- Severe ARDS
- Pa_{O2}/Fi_{O2} ≤ 100 mm Hg with PEEP ≥ 5 cm H2O
- Do not use extracorporeal CO_2 removal

SIRS

- Systemic Inflammatory Response Syndrome
- Fever >38C OR <36C
- Heart rate >90/min
- Respiratory rate >20/min
- pCO_2 <37 mmHg
- WBC >12,000 /fL OR <4,000 /fL with 10% bands
- May lead to multi-organ failure

Therapy

- Mechanical ventilation
- O_2 under positive pressure
- Low tidal volume and prone ventilation
- Diminish diaphragm respiratory effort to avoid fatigue
- Hemodynamic support with crystalloids and pressors
- Steroids
- If pregnant, within first 7 days of presentation of damage, and need for maturation of fetal lungs, administer dexamethasone
- If no need for maturation of fetal lungs, administer methylprednisolone as it does not cross placenta

Therapy

- Extracorporeal mechanical oxygenation (ECMO) as bridge to lung transplantation
- Mortality rate 40-50%
- Highest in those with increased BNP, Troponin I
- 60% of survivors will reach normal pulmonary function in 5 years

ARDS



Diffuse, bilateral alveolar infiltrates without pleural effusions, consistent with acute respiratory distress syndrome (ARDS).

Note that the patient has an endotracheal tube (red arrow) and has a central venous catheter (black arrow).

Fig. e24-28 Accessed 03/17/2010

ARDS



“Shock” lung

https://web.duke.edu/pathology/Week11-12/images/large/path40-01.jpg
Accessed 02/20/2020

“Shock” lung



https://image.slidesharecdn.com%2Fhemodynamicdisordersthrombosisandshock-131203140434-phpapp02%2F95%2Fhemodynamic-disorders-thrombosis-and-shock-practical-pathology-5-638.jpg%3Fcb%3D1386079560 Accessed 02/20/2020



Source: J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo: Harrison's Principles of Internal Medicine, 20th Edition

J. Larry Jameson, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, Dan L. Longo, Joseph Loscalzo

TABLE 287-1

Common Interstitial Lung Disease Findings

	IPF	Nonspecific Interstitial Pneumonia	Respiratory Bronchiolitis Associated ILD	Systemic Sclerosis Associated ILD	Sarcoidosis
Clinical symptoms	Gradual onset of SOB, dry cough. Unusual in younger adults.	Subacute onset of SOB, dry cough. Frequently associated with other conditions.	Can be asymptomatic, or have SOB, and cough.	Gradual onset of SOB, dry cough. Fatigue, tightening of skin, exaggerated cold response, reflux, and difficulty swallowing.	Can be asymptomatic, or have SOB, and cough. Can also have fatigue, palpitations, eye, skin, and joint findings.
Physical examination findings	Frequent rales at lung bases, digital clubbing is common.	Frequent rales. Clubbing is less common.	Rales common. Clubbing is rare.	Can have rales in isolation. Also skin thickening, joint swelling, and telangiectasias.	Can be normal, rales may be present. Can have skin findings, joint pain, and enlarged lymph nodes.
Exposures	Idiopathic but many exposed to smoke. Genetic findings may explain >1/3 of the risk of the disease.	Can be idiopathic but should prompt consideration for associated conditions.	Strong association with smoking.	Mostly unknown, some debate about solvent and silicate exposures.	Mostly unknown, although silicate dusts thought to play a role in some cases.
HRCT findings	Bilateral subpleural reticular changes most prominent in lower, posterior lung zones. Traction bronchiectasis and honeycombing common. Classic UIP pattern is considered diagnostic.	Peripheral subpleural ground glass and reticular patterns. Traction bronchiectasis is common but honeycombing is rare. HRCT not diagnostic.	Diffuse patchy centrilobular ground glass nodules.	Can have UIP or NSIP patterns, also dilated esophagus, occasional mediastinal calcifications, and pulmonary vascular enlargement.	Can have mediastinal and hilar lymphadenopathy. Peribronchovascular reticular-nodular findings.
Histopathology	UIP pattern including fibroblastic foci, temporal and spatial heterogeneity, honeycombing.	Cellular or fibrotic pattern of NSIP. More uniform than a UIP pattern.	Respiratory bronchiolitis with adjacent inflammatory and fibrosing changes. Pigment laden macrophages.	Both UIP or NSIP patterns can occur.	Non-caseating granulomas.
Clinical course	50% 3–5 year mortality.	18% 5-year mortality.	25% 7-year mortality.	20–30% 10-year mortality.	Generally low but varies by state.

Abbreviations: HRCT, high resolution chest CT; ILD, interstitial lung disease; NSIP, non-specific interstitial pneumonia; SOB, shortness of breath; UIP, usual interstitial pneumonia

Interstitial pulmonary fibrosis

- Once referred to as usual interstitial pneumonia (UIP) or idiopathic pulmonary fibrosis (IPF).
- >60 years of age
- Indolent presentation
- Dyspnea on exertion
- Dry cough
- History of smoking
- Digital clubbing
- End inspiratory respiratory crackles in bibasilar lungs
- Wheezing is uncommon

Interstitial pulmonary fibrosis

- Decreased total lung capacity (TLC)
- Decreased forced vital capacity (FVC)
- Decreased DLCO
- Ventilation-perfusion mismatch from ventilation of lung tissue with capillary destruction and perfusion of under ventilated alveoli
- Smaller component due to reduced diffusion across a fibrotic alveolar septa

Interstitial pulmonary fibrosis

- The etiology is unknown.
- IPF may result from repeated episodes of alveolitis.
- Damage of alveolar epithelium (or pneumocytes) is a key event
- The inflammatory response in IPF is thought to be of the T_{H2} type.
- Thus, eosinophils, mast cells, and IL-4 and IL-13 are found in the lesions.
- Reparative changes give rise to exuberant (nodular) fibroblastic proliferation with alveolar septal fibrosis and alveolar enlargement
- TGF-β expressed at these sites.

Mechanism

- TGF-β_1 Thought to be driver of the process
- Negatively regulates telomerase activity, facilitating epithelial cell apoptosis.
- Downregulates production of caveolin-1, the primary structural protein permitting invaginations in plasma cell mebranes
- Associated with receptor mediated endocytosis and with integrin signaling.
- Aberrant WNT/ β-catenin signaling pathway may be related to abnormal remodeling

Interstitial pulmonary fibrosis

- High resolution CT (UIP pattern):
- Subpleural bibasilar reticular opacity
- Clustered cystic airspaces, 3 - 10 mm in diameter (Honeycomb change)
- Traction bronchiectasis
- The presence of extensive ground glass opacities, bronchovascular changes, micronodules, mosaic attenuation, or an upper lung predominance should raise suspicion for an alternative diagnosis

Interstitial lung disease

- Non-specific interstitial pneumonia (NSIP)
- Women
- Non-smokers
- 40-50 years of age
- Also associated with connective tissue disorder (systemic sclerosis, polymyositis)
- May respond to steroids and immunosuppression

Interstitial lung disease

- Crytogenic organizing pneumonia (COP)
- 50–60 years of age
- Often presents as a subacute flu-like illness, with cough, dyspnea, fever, and fatigue.
- Inspiratory rales
- Restrictive lung disease
- Also associated with connective tissue disorder (systemic sclerosis, polymyositis) or cancer
- May respond to steroids and immunosuppression

Bronchiolitis

- Insidious onset of cough and dyspnea.
- Precipitated by toxic fumes, viral infections, organ transplantation, connective tissue disease.
- Irreversible airflow obstruction and air trapping on pulmonary function testing.
- Minimal findings on chest radiograph
- Constrictive bronchiolitis (also referred to as obliterative bronchiolitis, or bronchiolitis obliterans)
- Heterogeneous airflow obstruction and air trapping on chest CT scan.
- Responds poorly to steroids

Interstitial pulmonary fibrosis

Reticular nodular opacities bilaterally with small lung volumes consistent interstitial pulmonary fibrosis (IPF).

Fig e24-16 Accessed 03/17/2010

Interstitial pulmonary fibrosis



Intersitial pulmonary fibrosis (IPF).
Classic findings include traction bronchiectasis (black arrow) and honeycombing (red arrows). Note subpleural, basilar predominance of the honeycombing.

Fig. e24-17 Accessed 03/17/2010

Histopathology

- IPF (UIP pattern)
- Subpleural reticulation associated with honeycomb changes alternating with areas of preserved normal lung architecture
- Fibroblast foci
- Subepithelial collections of myofibroblasts and collagen
- NSIP
- Interstitial inflammation and fibrosis with a uniform appearance
- Rare to find either honeycomb change or fibroblast foci

Histopathology

- COP
- Patchy regions of organizing pneumonia with granulation tissue
- Commonly involves the small airways, alveolar ducts, and alveoli with surrounding inflammation
- Can involve the alveolar walls
- Sarcoidosis
- The hallmark histopathologic feature is presence of non-caseating granulomas
- Exclude the presence of malignancy or vasculitis



Interstitial pulmonary fibrosis

(A) Areas of fibrosis are mainly located in the peripheral zones of secondary lobules. (B) Patchy dense fibrosis affects the peripheral area inside the lobule and the perivenular area (arrowhead). (C) The fibroblastic focus consists of fibroblasts and myofibroblasts; it is covered by a cuboidal lining epithelium. (D) Microscopic honeycomb cysts are often covered by columnar ciliated epithelium. (E) Elastica van Gieson stain highlights the architectural destruction, which can be seen as thick fragmental elastic fibers. (F) Elastic fibers accumulate in the peripheral areas of secondary lobules.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772910/figure/f1-ccrpm-suppl.1-2015-123/
Accessed 01/10//2020



A. Idiopathic pulmonary fibrosis
B. Non-specific interstitial pneumonia
C. Cryptogenic organizing pneumonia:
D. Sarcoidosis



Source: J.L. Jameson, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J. Loscalzo: Harrison's Principles of Internal Medicine, 20th Edition

A. Idiopathic pulmonary fibrosis
B. Non-specific interstitial pneumonia
C. Cryptogenic organizing pneumonia:
D. Sarcoidosis

Lung transplant rejection

- Bronchial artery sparing improves survival
- Acute transplant rejection presents with fever, dyspnea, cough and pulmonary infiltrates.
- The absence of ground glass change on x-ray excludes acute rejection
- Transbronchial biopsy needed to exclude opportunistic agent.

Lung transplant rejection

- Chronic rejection leads to organizining pneumonitis with fibrosis and lymphocytic infiltrates obliterating bronchioles (bronchiolitis obliterans organizing pneumonia or BOOP)
- 75% 1 year survival
- 50% 5 year survival
- 26% 10 year survival



Bronchiolitis obliterans with hyalinizing change

Arrow points to Masson body (immature loose collagen in a polypoid shape) in bronchiolar lumen

https://www.pathologyoutlines.com/topic/lungnontumorBOOP.html
Accessed 01/10/2020

Histopathology

- Fibroblastic plugs in alveolar sacs and ducts (organizing pneumonia) and bronchiolar lumen (bronchiolitis obliterans)
- Formed by spindled fibroblasts in pale staining matrix of immature loose collagen with polypoid shape (Masson body) or serpiginous or elongated form
- Organizing pneumonia sometimes extends from one alveolus to the next one through interalveolar fenestrae (butterfly pattern)

Histopathology

- Thickened alveolar septa with lymphocytes, plasma cells and histiocytes
- Alveolar architecture is usually preserved
- Foamy macrophage accumulation in surrounding airspace may be present
- Organizing granulation tissue is collagenized or hyalinized and harbors eosinophilic, lamellar and dense fibers
- If fibrin deposition is prominent, the lesion is more likely to be infection, eosinophilic pneumonia, vasculitis, or acute fibrinous organizing pneumonia (AFOP)

IPF therapy

- Calcium channel blockers and phosphodiesterase type 5 inhibitors are effective in symptom control.
- Pirfenidone, an MAPK38 inhibitor, blocks TGF-β, slowing progression of fibrosis
- Nanetidab is a multiple tyrosine kinase inhibitor that also slows progression of fibrosis
- 5 year survival rate is 20% - 30%
- Median survival is 2 - 3 years

Desquamative interstitial pneumonia

- A disease spectrum from respiratory bronchiolitis to respiratory bronchiolitis related interstitial lung disease as well as smoking related interstitial pneumonia
- Dyspnea on exertion
- Dry cough
- Digital clubbing
- End inspiratory fine crackles in bibasilar lung
- Fever
- Fatigue
- Weight loss

Desquamative interstitial pneumonia

- Decreased forced vital capacity (FVC)
- Decreased DLCO
- High resolution CT:
- Bilateral and subpleural ground glass opacity
- Middle to lower zones are affected predominantly; however, the upper zone can be involved
- Linear shadow, cystic spaces, emphysema, traction bronchiectasis and honeycombing

Desquamative interstitial pneumonia

- Alveolar septal fibrosis and lymphocytic infiltrate in bronchiolar and alveolar walls characterize the lesion.
- 60-90%, adult smokers
- GM-CSF secretion from airway epithelial cells
- Subsequent inflammation provokes macrophage response and accumulation
- Mutation to surfactant protein C or ABCA-3 in pediatric patients
- 6-30% mortality rate if interstitial fibrosis

Desquamative interstitial pneumonia



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078007/figure/F2/
Accessed 01/10/2020

The alveolar architecture is preserved and delimited by a fibrous thickening (blue) of alveolar walls.

Within these septae, slight mononuclear infiltrates may be seen. Alveolar spaces are filled with macrophages (red) (Trichrome, 200×).

HYPERSENSITIVITY PNEUMONITIS

Hypersensitivity pneumonitis

- Unlike asthma, which affects the larger airways, hypersensitivity pneumonitis affects the alveolar septae.
- Intense exposure to an antigen, followed by cough and dyspnea within 4-6 hours.
- Symptoms may last 24 hours following exposure
- With repeated exposure, may lead to pulmonary fibrosis.
- May resolve if offending antigen removed.

Hypersensitivity pneumonitis

- Acute:
- Airway centered inflammation with little fibrosis
- Neutrophilic infiltration with or without capillaritis
- Intra-alveolar fibrin deposition
- Subacute:
- Airway centered infiltration with fibrosis
- Lymphocytic infiltration with granulomas or giant cells with cholesterol clefts

Hypersensitivity pneumonitis

- Chronic:
- Predominantly airway centered inflammation with diffuse fibrotic change
- Lymphocytic infiltration with granulomas or giant cells with cholesterol clefts in 67% of cases
- Often overlaps with other airway centered interstitial fibrosis pneumonitides
- Bridging fibrosis (fibrotic band connecting bronchioles with each other and with lobular septa) and peribronchiolar metaplasia distinguish from interstitial pulmonary fibrosis

Hypersensitivity pneumonitis

- Immune-mediated condition that occurs in response to inhaled antigens that are small enough to deposit
- T_H1 inflammatory pattern.
- T_H17 lymphocyte subsets may be involved in the pathogenesis of the disease as well.
- Precipitating IgG antibodies against specific antigens identified.
- Toll-like receptors and downstream signaling proteins such as MyD88 are activated in HP, leading to neutrophil recruitment

Hypersensitivity pneumonitis

- Most patients have specific antibodies in their serum (Type III reaction).
- Antigens in bird droppings characterizes Bird Fancier's Lung.
- Thermophilic actinomycetes found in Air-conditioner Lung, Bagassosis.
- Micropolyspora faeni (found in moldy hay) characterizes Farmer's Lung.
- Saccharapolyspora rectivirgula and Eurotium amstelodami mold spores (found in hay) associated with Compost Worker's Lung

Hypersensitivity pneumonitis

- Aerosolized Mycobacterium Avium-intercellulare characterizes Hot Tub Lung
- Aspergillus clavatus from moldy barley is found in Malt Worker's Lung
- Cryptostroma corticale from moldy maple bark is found in Maple Bark Disease
- Bacillus subtilis is found in Domestic hypersensitivity pneumonitis and Detergent Worker's Disease
- Penicillium casei is found in Cheese Worker's Lung
- Proinflammatory cytokines IL-8 and MIP-1α increased in bronchoalveolar lavage fluid.
- Both CD4+ and CD8+ cells are increased.

Hypersensitivity pneumonitis

- Ill defined centrilobular nodules of ground-glass opacity on x-ray
- May be patchy and alternate with areas of hyperlucency (air trapping in bronchioles).
- Upper lobes usually involved.
- Large numbers of eosinophils suggest eosinophilic pneumonia, microfilarial infection, or aspergillosis.

Hypersensitivity pneumonitis

- Silo Filler's Lung is due to Nitrous dioxide injury and is not a hypersensitivity disease.
- Chemical Worker's Lung is due to toluene diisocyanate or trimellitic anhydride injury and is not a hypersensitivity disease
- Byssinosis presents as does asthma
- Cotton, hemp, linen fibers in textile workers
- May not be immunologic cause

Hypersensitivity pneumonitis

- High resolution CT
- In subacute forms of the disease, ground-glass airspace opacities are characteristic, as is the presence of centrilobular nodules.
- Expiratory images may show areas of air trapping that are likely caused by involvement of the small airways
- Reticular changes and traction bronchiectasis can be observed in chronic HP.
- Subpleural honeycomb
- Lung bases are frequently spared.

Hypersensitivity pneumonitis



Patchy ground-glass opacity and lobular hyperlucency.
Subacute farmer's lung.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932567/figure/F20/
Accessed 01/10/2020

Chronic change



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786616/figure/JCLINPATH2013201442F7/
Accessed 01/10/2020 Hypersensitivity pneumonitis

Centrilobular fibrosis with relative sparing of the septum and pleura (A, 20×, H&E). Centrilobular interstitial inflammation with extensive peribronchiolar metaplasia (arrow heads) (B and D, 40×, H&E), and rare interstitial giant cells or histiocyte aggregates of poorly formed granulomas (arrows) (C and D, 200x H&E)

Chronic change



EOSINOPHILIC SYNDROMES

TABLE 282-2

Pulmonary Infiltrates with Eosinophilia

Primary Pulmonary Eosinophilic Disorders
Acute eosinophilic pneumonia
Chronic eosinophilic pneumonia
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
Hypereosinophilic syndrome
Pulmonary Disorders of Known Cause Associated with Eosinophilia
Asthma and eosinophilic bronchitis
Allergic bronchopulmonary aspergillosis
Bronchocentric granulomatosis
Drug/toxin reaction
Infection (Table 282-4)
Parasitic/helminthic disease
Nonparasitic infection
Lung Diseases Associated with Eosinophilia
Cryptogenic organizing pneumonia
Hypersensitivity pneumonitis
Idiopathic pulmonary fibrosis
Pulmonary Langerhans cell granulomatosis
Malignant Neoplasms Associated with Eosinophilia
Leukemia
Lymphoma
Lung cancer
Adenocarcinoma of various organs
Squamous cell carcinoma of various organs
Systemic Disease Associated with Eosinophilia
Postradiation pneumonitis
Rheumatoid arthritis
Sarcoidosis
Sjögren's syndrome

Eosinophilic syndromes

- Dysregulated eosinophilopoiesis or an autoimmune process
- Pprominence of allergic features and the presence of immune complexes
- Heightened T cell immunity
- Altered humoral immunity as evidenced by elevated IgE and rheumatoid factor.
- Interleukin 5 (IL-5) has been hypothesized to play an etiologic role.

TABLE 282-3

Diagnostic Criteria of Acute Eosinophilic Pneumonia

Acute febrile illness with respiratory manifestations of <1 month in duration
Hypoxemic respiratory failure
Diffuse pulmonary infiltrates on chest x-ray
Bronchoalveolar lavage eosinophilia >25%
Absence of parasitic, fungal, or other infection
Absence of drugs known to cause pulmonary eosinophilia
Quick clinical response to corticosteroids
Failure to relapse after discontinuation of corticosteroids

Acute eosinophilic pneumonia

- Cough, dyspnea, malaise, myalgias, night sweats, and pleuritic chest pain
- Men
- 20-40 years of age
- No history of asthma
- High fevers, basilar rales, and rhonchi on forced expiration.
- Often mistaken for acute lung injury or acute respiratory distress syndrome (ARDS)
- Bronchial alveolar lavage (BAL) reveals >25% eosinophils.

Chronic eosinophilic pneumonia

- Cough, dyspnea, malaise, myalgias, night sweats, developing over several months
- Women
- 20-40 years of age
- Non-smokers
- History of asthma
- Migratory or bilateral peripheral or pleural based opacities on chest x-ray
- Rarely develop respiratory failure
- BAL eosinophils >60%

Allergic bronchopulmonary aspergillosis

- ABPA
- Occurs in response to allergic sensitization to antigens from Aspergillus species fungi.
- The predominant clinical presentation of ABPA is an asthmatic phenotype
- Often accompanied by cough with production of brownish plugs of mucus.
- ABPA has also been well described as a complication of cystic fibrosis.
- Central bronchiectasis is described as a classic finding on chest imaging

EGPA

- Eosinophilic granuloma with polyangiitis (Churg-Strauss)
- Eosinophilic vasculitis in the setting of asthma and involvement of multiple end organs
- Prodromal:
- This phase may persist for years.
- Patients have allergic rhinitis, nasal polyposis, asthma, or a combination.
- 2nd phase:
- Peripheral blood and tissue eosinophilia is typical.
- Chronic eosinophilic pneumonia and eosinophilic gastroenteritis.

EGPA

- 3rd phase:
- Potentially life-threatening vasculitis develops.
- Organ dysfunction and systemic symptoms common
- 9 years from onset of asthma
- May be precipitated by use of leukotriene modifiers and anti-IgE antibodies
- 75%, have neurologic manifestations
- Mononeuritis monoplex (chiefly, peroneal nerve)
- Cerebral hemorrhage and infarction
- 50%, develop dermatologic manifestations
- Palpable purpura, uriticarial rashes

EGPA

- 50%, cardiomyopathy and heart failure
- 25%, renal involvement
- Eosinophilic gastroenteritis
- Abdominal pain, diarrhea, colitis

EGPA

- Bilateral, nonsegmental, patchy infiltrates on chest x-ray
- Often migrate and may be interstitial or alveolar in appearance.
- Bilateral ground-glass opacity and airspace consolidation that is predominantly subpleural
- Reticulonodular and nodular disease without cavitation can be seen
- Pleural effusions and hilar adenopathy

Diagnostic criteria

- Any four of the following:
- Asthma
- Eosinophilia of > 10% in peripheral blood
- Paranasal sinusitis
- Pulmonary infiltrates, sometimes transient
- Histologic evidence of vasculitis with extravascular eosinophils
- Multiple mononeuropathy or polyneuropathy

Hypereosinophilic syndromes

- 40%, cough, dyspnea, pulmonary infiltrates
- Endomyocardial fibrosis may lead to pulmonary edema
- Restrictive cardiomyopathy
- Extra-pulmonary involvement as with EGPA
- High levels of eosinophils in BAL, tissue

Hypereosinophilic syndromes

- The myeloproliferative variants
- Splenomegaly
- Thrombocytopenia
- Anemia
- (Fip1L1-PDGFRα) fusion protein due to a chromosomal deletion of CHIC2 on 4q12
- Men
- 20-50 years of age
- Endomyocardial fibrosis common
- AML rare
- Not associated with ANCA

Hypereosinophilic syndromes

- Platelet-derived growth factor β (PDGFRβ), Janus kinase 2 (JAK2), and fibroblast growth factor receptor 1 (FGFR1) are other mutations seen
- Up to 50% of those who are untreated die within 3 months of diagnosis, whereas treated patients have a 6-year survival of >70%
- Many respond to imatinib
- Allogeneic stem cell transplantation

Hypereosinophilic syndromes

- The lymphoproliferative variants
- T cell clones with aberrant T-cell receptor arrangements
- Angioedema
- Hypergammoblobulinemia (especially, IgE)
- Circulating immune complexes
- Serum sickness
- Respond to steroids
- T-cell leukemia rare

TABLE 282-4

Infectious Causes of Pulmonary Eosinophilia

Löffler Syndrome
Ascaris Hookworm Schistosomiasis
Heavy Parasite Burden
Strongyloidiasis
Direct Pulmonary Penetration
Paragonimiasis Visceral larval migrans
Immunologic Response to Organisms in Lungs
Filariasis Dirofilariasis
Cystic Disease
Echinococcus Cysticercosis
Other Nonparasitic
Coccidioidomycosis Basidiobolomycosis Paracoccidioidomycosis Tuberculosis

Source: Adapted from P Akuthota, PF Weller: Clin Microbiol Rev 25:649, 2012.

Goodpasture's syndrome

- Autoimmune disease principally affecting men
- Type II hypersensitivity reaction
- Usually ages 15 - 29 years
- Simultaneous massive hemorrhagic interstitial pneumonitis and rapidly progressive (crescentic) glomerulonephritis (type I)
- Hemoptysis and hematuria
- May be preceded by chemical or drug exposure, viral infection or malignancy

Goodpasture's syndrome



May be difficult to distinguish from pulmonary edema.

In the majority of cases, there are bilateral, coalescent airspace opacities on chest x-ray, which in several days resolve to give reticular opacities in the same distribution

https://radiopaedia.org/articles/goodpasture-syndrome
Accessed 02/20/2020

Histology

- Lungs:
- Heavy, focal necrosis of alveolar wall
- Fibrous thickening of septa with mild hyperplasia of alveolar lining cells
- Organization of blood in alveolar space
- Hemosiderin laden macrophages
- Linear deposits of anti-GBM along basement membrane
- Kidney:
- Focal proliferative to crescentic glomerulonephritis
- Linear deposits of anti-GBM and C3 along basement membrane



DOI: 10.7326/0003-4819-89-5-635
Accessed 02/20/2020

Upper panels: transbronchial lung biopsy, a. Light microscopy, H&E x 300 b. Electron microscopy showing no electron-dense deposits, x 18 000 c. Immunofluorescent staining showing strongly positive linear deposits of IgG, x 200 . Lower panels: kidney biopsy, d. Normal light microscopy, x 300 . e. Electron microscopy showing normal glomerular basement membranes and no electron-dense deposits, x 9000 . f. Strongly positive linear deposits of IgG by immunofluorescent staining; x 200 .

Goodpasture's





Fig. e9-12 Accessed 03/17/2010

There is segmental necrosis with a break of the glomerular basement membrane and a cellular crescent (left). Immunofluorescence for anti-GBM hows linear staining of the glomerular basement membrane with a small crescent at 1 o'clock. (ABF/Vanderbilt Collection.)

Granulomatosis with polyangitis

- Once known as Wegner's granulomatosis
- 90% Upper respiratory tract involvement (nose)
- 95% Lower respiratory tract involvement (lungs)
- 80% Renal involvement (glomerulus)
- Skin involvement.
- May also see uveitis.
- Necrotizing granulomatous inflammation of the arterioles.
- Hematuria with red cell casts
- Antibodies to PR3-ANCA and MPO-ANCA
- Corticosteroids and cyclophosphamide therapy.
- Mortality 100% if untreated.

Anti-neutrophil cytoplasmic antibodies

- Antibodies to cellular constituents
- Do not form circulating immune complexes
- Not found in vascular lesions ("pauci-immune")
- Anti-proteinase-3 ANCA (PR3-ANCA)
- Was once known as c-ANCA
- Shares homology with microbial peptides
- Anti-myeloperoxidase ANCA (MPO-ANCA)
- Was once known as p-ANCA
- Myeloperoxidase is a lysozomal granule associated with free radical formation
- May be generated by drug (propothiouracil)

Anti-neutrophil cytoplasmic antibodies

- Non PR3 and MPO ANCAs may be seen in other disorders that do not present as vasculitis
- Inflammatory bowel disease
- Sclerosing cholangitis
- Rheumatoid arthritis
- All are upregulated by TNF
- Activated neutrophils lead to tissue damage

Histopathology

- Liquefactive or coagulative necrosis in lungs
- Profusion of eosinophils
- Multinucleated giant cells, as part of poorly formed granulomas, surrounded by pallisading histiocytes and giant cells with central necrosis
- Destructive leukocytic angiitis of arteries and veins outside of the necrotic granuloma by neutrophils, plasma cells and eosinophils
- Scanty lymphocytes and plasma cells
- Bronchial wall is rarely involved

Histopathology

- Fulminant subtype has predominance of exudative changes
- Fibrous scar subtype has marked collagenous stroma
- Small vessel variant involves alveolar septal capillaries instead of large arteries or veins (resembles SLE)

Limited granulomatosis with polyangiitis

- More common in males
- >45 years of age
- Limited granulomatosis does not involve kidney
- Rarely associated with diffuse pulmonary hemorrhage
- Waxing and waning of pulmonary nodules and infiltrates on chest x-ray is relatively specific

Limited granulomatosis with polyangiitis

- PR3-ANCA positive: diffuse cytoplasmic staining directed against neutrophil serine proteinase 3
- 90% positive in active generalized disease
- 60% positive in limited disease
- MPO-ANCA directed against myeloperoxidase is negative
- If positive, is polyarteritis or crescentic glomerulonephritis

PNEUMOCONIOSES

Comparison of granulomas



(**a**) Lymphangitic distribution of granulomas in pulmonary sarcoidosis. (**b**) Clusters of histiocyte-filled alveolar spaces and alveolar septae expanded with lymphocytes in cobalt pneumoconiosis. (**c**) Perivascular granuloma from intravenous talcosis. (**d**) Granuloma expanding the bronchiolar submucosa and constricting the lumen in a case of hypersensitivity pneumonitis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2488176/figure/Fig3/
Accessed 01/10/2020

Sarcoid

- 25% of cases of interstitial lung disease
- 29-39 years of age peak incidence.
- Fever, weight loss, fatigue, dyspnea
- Women predominate
- Non-smokers
- Extrapulmonary signs may be the initial presentation
- Etiology undetermined
- Infectious origin suspected
- Sarcoidosis can lead to alveolar septal fibrosis, typically in upper lobes of lung.

Sarcoid

- 10-15 times more common in those of sub-Saharan origin.
- More likely to develop ocular and granulomatous skin involvement, granulomatous hepatitis, and more frequently suffer chronic, debilitating disease
- Cardiac (up to 85%) and ocular disease are more common in Japanese patients
- Joint symptoms and erythema nodosum are more common in northern Europeans

Extrapulmonary signs

- Cutaneous
- Erythema nodosum noted in 22%
- Septal panniculitis, not granulomatous
- Waxy skin plaques on lids
- Lupus pernio characteristic
- Violaceous indurated area on face, particularly nasal ala
- Scar sarcoid is granulomatous, precipitated by trauma
- Granulomatous hepatitis in 25%
- May lead to biliary disease

Erythema nodosum

Source: Wolff K, Johnson RA: *Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 6th Edition:* http://www.accessmedicine.com

Fig. 7-23 Accessed 07/16/2010

Extrapulmonary signs

- Cardiac disease in 5-25%
- Involvement does not correlate with extent of pulmonary disease
- Arrhythmias correlate with extent of cardiac disease
- Septum and left ventricle common sites of disease
- Neurologic disease
- CN VII palsy 10-25%
- Cerebral white matter plaques resemble those of multiple sclerosis
- Granulomatous nephritis in 7-23%

Extrapulmonary signs

- Uveitis in as many as 80%
- Two incidence peaks
- One is in third decade (acute)
- The second is in sixth-seventh decade
- Usually involves anterior chamber

Uveitis



(A) Scleritis in a patient with sarcoidosis. (B) Optic nerve swelling on fundoscopic exam.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756667/ Fig. 2 (*Courtesy of* Dr G. Papaliodis, Massachusetts Eye and Ear Infirmary, Boston, MA.)
Accessed 02/20/2020

Sarcoid

- 10-20% hypercalcemic
- Up to 40% have hypercalcuria
- Epithelioid histiocytes may produce Vitamin D.
- Convert inactive Vitamin D
- Hypercalcemia may be asymptomatic.
- Serum Ca^{2+} >11mg/dl requires treatment as this is associated with progression.

Mechanism

- T_{H1}-driven disorder
- Upregulation of co-inhibitory receptors on $CD4^+$ T cells, likely from persistent antigen exposure.
- Major histocompatibility complex (MHC) class II molecules on antigen-presenting cells contain an autoantigen that is recognized by the T-cell receptor (TCR) of the responding T-cells of sarcoidosis patients leading to their clonal expansion.
- Strong associations of MHC-II alleles and TCR subfamilies with the clinical course of sarcoidosis

Mechanism

- HLA-DRB1*11:01 increases risk in both Africans and Europeans
- HLA-DRB1*03:01 has a strong association with increased disease risk but also with disease resolution in Europeans.
- In Africans, 03:01 was protective against disease risk, whereas 03:02 was associated with disease risk and resolution
- ANXA11 (annexin) gene mutation at 10q22.3 in Africans
- Calcium dependent binding of phospholipids (e.g., cell walls)



Annals ATS, 2017
https://www.atsjournals.org/doi/abs/10.1513/AnnalsATS.201707-565OT

Sarcoid

- Biopsy is diagnostic
- Epithelioid granuloma
- High yield sites:
- Lacrimal glands
- Liver
- Lung
- Bronchioalveolar lavage if no clear diagnosis
- Angiotensin converting enzyme elevated.
- CD4:CD8 ratio markedly increased
- IL-2, IFN-γ, IL-8, TNF-α, MIP-1^{α} increased both in serum and bronchial fluids.
- Type IV reaction

Sarcoid

Reticular nodular opacities bilaterally with bilateral and mediastinal adenopathy. Apical prominence.

Characteristic

Fig. e24-21 Accessed 03/17/2010

Sarcoid



Fig. 6-20 Accessed 07//16/2010

In the dermis, numerous "naked" (noncaseating) granulomas consisting of epithelioid cells and scant lymphocytes are seen.
The overlying epidermis is atrophic.

Asteroid bodies (eosinophilic, star-shaped inclusions), and Schaumann bodies (concentrically calcified bodies) noted on biopsy.

Sarcoid

- Two-thirds spontaneously remit within ten years.
- 60-80% stage I (bilateral adenopathy)
- 50-60% stage II (adenopathy and fibrosis)
- 30% stage III (fibrosis)
- Relapses uncommon
- Fewer than 5% die from pulmonary fibrosis.

Sarcoid variants

- Uveoparotid fever or Heerfordt syndrome.
- Uveitis concomitant with fever, parotitis, and facial nerve paralysis
- Löfgren syndrome
- Acute sarcoid arthritis concomitant with bilateral hilar lymphadenopathy and erythema nodosum
- The ankles are most commonly affected, followed by the knees, wrists, elbows, wrists, and metacarpophalangeal joints.
- Remits spontaneously

Therapy

- Prednisone if symptomatic or if extrapulmonary organ dysfunction
- Does not affect survival
- Begin osteoporosis therapy
- Hydrochloroquine if extensive skin disease
- Cyclophosphamide or methotrexate if chronic or refractory disease.

Pneumoconiosis

- 25% of cases of interstitial lung disease
- Very few exposed workers (to mineral dust) develop occupational respiratory disease.
- Genetic variation of serum and red cell proteins correlate with susceptibility to developing silicosis, chronic bronchitis, and occupational asthma.
- Particles 1-5 um reach bifurcation of respiratory bronchioles and alveolar ducts
- Particles <0.5 um reach alveoli and are phagocytized

Pneumoconiosis

- Dust induced.
- Black lung (silica in coal dust)
- Brown lung (cotton fibers)
- Popcorn lung (diacetyl, the flavor of movie theater buttered popcorn)
- Asbestos
- Kaolin
- Talc
- Mica

Pneumoconiosis

- Coal workers pneumoconiosis (CWP) is related to silica content of coal.
- Coal dust is minimally fibrogenic
- Usually asymptomatic
- Anthracotic pigment in hilar nodes and interstitial tissue
- "Dust cells" are macrophages containing pigment
- Small opacities in upper lobes and superior portions of lower lobes
- Deposits adjacent to respiratory bronchioles may produce centrilobular emphysema

Pneumoconiosis

- Progressive massive fibrosis (PMF) as late stage disease
- Large opacities which may have necrotic centers
- May have large cavitating nodules (Caplan syndrome)
- Highly soluble particles are likely to appear in the pulmonary fluids.
- Birefringent with polarized light
- No increased risk of tuberculosis or cancer
- May develop secondary pulmonary hypertension and right heart failure

Silicosis

- Acute silicosis:
- Alveoli are filled with eosinophilic, fine, proteinaceous-like material
- Surfactant abnormality
- Antibody to GM-CSF
- Pro-inflammatory cytokines and neutrophil elastases lead to alveolar damage
- Involvement of upper lobe with nodules and “eggshell-like” calcification of hilar nodes noted on chest x-ray.

Silicosis

- Chronic silicosis:
- Nodular fibrosis, progressing to progressive massive fibrosis and scarring.
- 15-20 year lag time
- Honeycomb lung.
- Macrophage dysfunction in silicosis predisposes to mycobacterial infection

Silicosis

Eggshell calcification typical of silicosis

https://image.slidesharecdn.com/presentationlastsilicosis-140823154122-phpapp02/95/pneumoconiosis-silicosis-5-638.jpg?cb=1408808630

Accessed 02/20/2020

Acute silicosis. This high-resolution computed tomography scan shows multiple small nodules consistent with silicosis but also diffuse ground-glass densities with thickened intralobular and interlobular septa producing polygonal shapes. This has been referred to as “crazy paving.”

Silicosis



Healthy lung

Early stages



Late stages

https://www.cadcr.com/wp-content/uploads/2017/02/1-1.jpg
Accessed 02/20/2020

Silicosis



Left: Scarring in upper lobe with dense pleural thickening (arrow)
Right: Various presentations of granuloma formation and inflammation.

https://image.slidesharecdn.com/silicosis-160524172952/95/silicosis-6-638.jpg?cb=1464111145

Silicosis



https://www.microscopyu.com/assets/gallery-images/pathology_silicosisinlung40x02.jpg
Accessed 02/20/2020

Silicosis



https://classconnection.s3.amazonaws.com/918/flashcards/637918/jpg/silicosis1354226310970.jpg
Accessed 02/20/2020

Silicosis



https://c1.staticflickr.com/9/8165/7462024074_3e030e5af1_b.jpg
Accessed 02/20/2020

Asbestosis

- Asbestosis is a diffuse interstitial fibrosing disease of the lung that is directly related to the intensity and duration of exposure
- 10+ year lag time
- Asbestos is a generic term for several different mineral silicates.
- All are amphibole types with the exception of chrysotile, which is serpentine.
- Chrysotile is serpentine, fine
- Associated with lung cancer
- Lung cancer risk increases in smokers

Asbestosis

- Crocidolite is straight and rigid
- Associated with fibrosis and mesothelioma
- Pleural and diaphragmatic plaques arise from serosal lining cells
- May have associated effusion
- Not related to smoking
- Oxidative injury due to the generation of reactive Oxygen species by the transition metals on the surface of the fibers as well as from cells engaged in phagocytosis.
- Macrophages coat fibers with ferritin (ferruginous bodies)
- Are golden brown



A

Asbestosis. A. Frontal chest radiograph shows bilateral calcified pleural plaques consistent with asbestos-related pleural disease. Poorly defined linear and reticular abnormalities are seen in the lower lobes bilaterally. B. Axial high-resolution computed tomography of the thorax obtained through the lung bases shows bilateral, subpleural reticulation (black arrows), representing fibrotic lung disease due to asbestosis. Subpleural lines are also present (arrowheads), characteristic of, though not specific for, asbestosis. Calcified pleural plaques representing asbestos-related pleural disease (white arrows) are also evident.



B

Asbestosis. A. Frontal chest radiograph shows bilateral calcified pleural plaques consistent with asbestos-related pleural disease. Poorly defined linear and reticular abnormalities are seen in the lower lobes bilaterally. B. Axial high-resolution computed tomography of the thorax obtained through the lung bases shows bilateral, subpleural reticulation (black arrows), representing fibrotic lung disease due to asbestosis. Subpleural lines are also present (arrowheads), characteristic of, though not specific for, asbestosis. Calcified pleural plaques representing asbestos-related pleural disease (white arrows) are also evident.

Berylliosis

- Diffuse interstitial fibrosis
- Non-caseating granulomas
- May be confused with sarcoid
- Only pneumoconiosis that responds to steroids
- Increased risk of lung cancer
- Dispersive x-ray analysis to determine presence in tissue

Berylliosis



https://www.researchgate.net/figure/A-Hematoxylin-eosin-staining-of-lung-tissue-from-a-study-patient-with-beryllium_fig1_8339346

PRIMARY PULMONARY HYPERTENSION

Primary pulmonary hypertension

- Presents with progressive dyspnea
- Age 20–40 years
- Women 3:1
- Dyspnea
- Tachypnea (>20/minute)
- Pleurisy (increased hydrostatic pressures)
- Accentuated P_2.
- Tricuspid regurgitation murmur.
- Early systolic click.
- 15% familial, mutation at 2q33
- In children, associated with HLA-DR3

Primary pulmonary hypertension

- A palpable P_2 has a positive likelihood ratio, LR+, of a mean pulmonary artery pressure >50 mmHg, of 3.6; LR-, 0.05.
- Sustained left lower parasternal movement (positive likelihood ratio, LR+, of a mean pulmonary artery pressure >50 mmHg, 3.6; LR-, 0.4).
- Right heart catheterization for diagnosis.
- Mean pulmonary artery pressure >20 mmHg

WHO classification

- Group 1 Pulmonary arterial hypertension
- Idiopathic
- Heritable
- BMPR2, ALK1, SMAD9, caveolin, KCNK3 mutations
- Methamphetamine
- Left to right cardiac shunts (Eisenminger)
- Scleroderma
- Portal hypertensions
- Schistosomiasis

WHO classification

- Group I’ Pulmonary veno-occlusive disease,
- Pulmonary capillary hemangiomatosis
- Idiopathic
- Heritable
- EIF2AK4 mutation
- Radiation
- Group I” Persistent pulmonary hypertension of the newborn
- Right to left cardiac shunt

WHO clasification

- Group II Pulmonary arterial hypertension caused by left heart disease
- Systolic or diastolic dysfunction
- Mitral or Atrial valve disorders
- Left outflow tract obstruction
- Pulmonary venous stenosis

WHO classification

- Group III Pulmonary hypertension caused by lung disease
- COPD
- Interstitial fibrosis
- Sleep apnea
- Exposure to high altitude
- Group IV Chronic arterial obstruction
- Chronic thromboembolic disease
- Angiosarcoma
- Arteritis
- Congenital pulmonary artery stenosis
- Hydatid cysts

WHO classification

- Group V Pulmonary hypertension associated with other conditions
- Sickle cell anemia
- Sarcoid
- Fibrosing mediastinitis
- Glycogen storage disease or Gaucher disease
- Histiocytosis

Primary pulmonary hypertension

- Histopathology:
- Grade 1 Medial hypertrophy of muscular and elastic arteries
- Grade 2 Intimal fibrosis and atheromas of pulmonary artery are found.
- Grade 3 Near obliteration of vessels
- Grade 4 Plexiform (angiomatoid) change
- Capillary proliferation associated with vessel obliteration is a sign of severe pulmonary hypertension.

Primary pulmonary hypertension

- Mechanism:
- Monoclonal proliferation of endothelial cells
- PPH is a neoplasm
- Endothelial dysfunction results in an increase of endothelin-1 (decrease of NO) and of thromboxane and vascular endothelial growth factor (VEGF)
- Dysregulate elastase and MMPs
- Downregulation of inward voltage gated K^+ channels
- Serotonin excess
- Leads to Chronic vasoconstriction

Primary pulmonary hypertension

- BMPR2 mutation at 2q33 most common
- Inhibition of proliferation of vascular smooth muscle
- Favors apoptosis of the vascular smooth muscle
- Similar mutation in pulmonary veno-occlusive disease

Treatment

- If it is caused by left heart disease
- Optimize left ventricular function
- Valve replacement
- Groups II or III
- Do not use vasoactive agents
- High dose calcium channel blockers are useful in only those 5% of patients who are vasoactive

Outcomes

- Untreated, 24 months survival
- Die of cor pulmonale
- With appropriate therapy, survival rates are:
- 1 year 85%
- 3 year 68%
- 5 year 57%
- 7 year 49%
- For patients with idiopathic/familial PAH, survival rates were 91%, 74%, 65%, and 59%

Primary pulmonary hypertension



AC, adenylate cyclase; AMP, adenosine monophosphate; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; EC, endothelial cells; ET_A, endothelin receptor A, ET_B, endothelin receptor B; GMP, guanosine monophosphate; GTP, guanosine triphosphate; IP, prostaglandin I receptor; PDE, phosphodiesterase; sGC, soluble guanylate cyclase

https://en.wikipedia.org/wiki/Pulmonary_hypertension#/media/File:Molecular_Pathology.png Accessed 02/20/2020

Pulmonary hypertension



Note the enlarged pulmonary arteries (red arrows) visible on both PA and lateral films.

Fig. e24-49 Accessed 03/17/2010

Primary pulmonary hypertension with emphysema



https://en.wikipedia.org/wiki/Pulmonary_hypertension#/media/File:PulArtHyperandEmphysemaMark.png Accessed 02/20/2020

Primary pulmonary hypertension



https://en.wikipedia.org/wiki/Pulmonary_hypertension#/media/File:Pulmonary_hypertensive_arteriopathy_(4348170715).jpg
Accessed 02/20/2020

Cor pulmonale



https://en.wikipedia.org/wiki/Pulmonary_hypertension#/media/File:Heart_-_cor_pulmonale-_right_ventricular_hypertrophy_(4351912426).jpg
Accessed 02/20/2020

PULMONARY EMBOLISM

Pulmonary embolism

- Dyspnea of sudden onset.
- Often pleuritic chest pain.
- May have hemoptysis.
- Half the patients will have a pleural effusion.
- May not be hypoxemic
- Saddle vein embolus blocks pulmonary artery at branch site, potentially fatal
- Antiphospholipid antibodies present in 2-8%
- Factor V Leiden present in 11% with deep vein thrombosis.

Risk factors

- Major cause of death in pregnancy and up to 12 weeks post-partum
- Recent major surgery or trauma within three months
- Bedrest of three days or more or travel of four hours or more within the past month
- Active malignancy
- Central vein instrumentation within three months
- Inherited thrombotic disorders
- Chronic heart failure or chronic lung disease.
- Oral contraceptives containing 50 ug/day of estrogen (also, with NSAID)
- Exponential increase with age after 40 years old

Hemodynamic instability

- Cardiac arrest defined as need for cardiopulmonary resuscitation
- Obstructive shock defined as the presence of all of the following:
- Systolic blood pressure < 90 mm Hg or vasopressors required to achieve blood pressure ≥ 90 mm Hg despite adequate filling status
- End-organ hypoperfusion, such as altered mental status, cold and clammy skin, oliguria or anuria, and increased serum lactate

Hemodynamic instability

- Persistent hypotension
- Systolic blood pressure < 90 mm Hg or systolic blood pressure drop ≥ 40 mm Hg lasting longer than 15 minutes and not caused by new-onset arrhythmia, hypovolemia, or sepsis

Pulmonary embolism

- High risk: sustained hypotension (BP <90 mmHg)
- Intermediate risk: normotension but with evidence of right ventricular dysfunction or myocardial necrosis
- RV dilation on echocardiogram
- Elevation of BNP
- EKG abnormalities:
- New right bundle branch block
- Anteroseptal ST elevation or depression
- T-wave inversion
- Elevation of troponin
- Low risk shows no such changes

Pulmonary embolism

- 80% of patients have deep (leg) vein thrombosis.
- Calf vein thrombosis may extend into popliteal
- Positive Homan's sign (pain on dorsiflexion of ankle)
- 48% of patients with deep vein thrombosis have pulmonary emboli (often asymptomatic)
- Upper extremity thrombi may also produce pulmonary emboli
- Pelvic vein thombosis may also lead to pulmonary embolism
- 4% mortality at 30 days
- 13% mortality at one year

Pulmonary embolism

- Normal ventilation-perfusion scan excludes pulmonary embolus.
- High probability scan, 90% chance of pulmonary embolus; low probability, 30%.
- Spiral CT Angiography definitive.
- Generalized perfusion defect in main pulmonary artery with extension to lobar branches.
- May show pleural based wedge infarct.
- Negative D-dimer excludes pulmonary embolus.

Treatment

- High Risk
- Treat Shock
- IV Unfractionated Heparin (UFH)
- Binds Anti-thrombin III
- Systemic thrombolytic therapy
- Hypotensive or hemodynamic decompensation
- AND without high bleeding risk
- Thrombolysis is associated with better long-term outcomes.
- 25% post-thrombotic swelling

Treatment

- Surgical embolectomy if contraindication to thrombolysis
- Recent surgery, hemorrhagic stroke, significant active or recent bleeding contraindications
- Mortality rates up to 60%

Treatment

- Stable patients
- Direct Oral Anticoagulants (DOAC) preferred over vitamin K antagonists
- Low molecular weight heparin with vitamin K antagonists if DOAC contraindicated
- DOAC increase risk of arterial thrombosis if antiphospholipid syndrome
- LMWH and fondaparinux are suggested over IV unfractionated heparin
- Post-thrombotic swelling common
- Pregnant patients as well as those breast feeding
- Heparin compounds are the preferred anticoagulants in pregnancy

Treatment

- If provoked PE (trigger identified) with transient risk factor (surgical or nonsurgical)
- Anticoagulate for 3 months
- If first unprovoked or idiopathic PE (no identified trigger)
- Anticoagulate for at least 3 months
- Discontinue anticoagulation after 3 months if high risk of bleeding or secondary to transient/reversible risk factors
- If second unprovoked PE:
- Anticoagulate indefinitely unless PE is provoked by major transient or reversible factors or if bleeding risk is high

Treatment

- Vena cava interruption by the insertion of a filter into the inferior vena cava (Greenfield filter) is only indicated in the following settings:
- Patients with acute venous thromboembolism who have an absolute contraindication to anticoagulant therapy
- Patients with massive PE who survived but in whom recurrent embolism invariably will be fatal
- Patients who have objectively documented recurrent venous thromboembolism in the face of adequate anticoagulation

High probability ventilation/perfusion scan



A



B

A, perfusion; B, ventilation revealing several mismatched defects in the left lung.

(Courtesy of Marcus Chen, MD, Department of Nuclear Medicine, University of Colorado Health Sciences Center.) Fig. 19-1 Accessed 04/27/2010

Spiral CT scan



Source: Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY: *Williams Obstetrics, 23rd Edition:* http://www.accessmedicine.com

There is enhancement of the pulmonary artery with a large thrombus on the right (arrow) consistent with pulmonary embolism. Contrast administered.

(Courtesy of Dr. Michael Landay.)

Fig. 47-1 Accessed 04/27/2010

Pulmonary embolism



https://webpath.med.utah.edu/LUNGHTML/LUNG062.html
Accessed 01/10/2010

A "saddle embolus" that bridges across the pulmonary artery from the heart as it divides into right and left main pulmonary arteries. Such a saddle embolus is a cause for sudden death.
The surface is somewhat irregular, and there are areas of pale tan to white admixed with dark red areas. The thrombus often has the outlines of the vein in which it formed

Pulmonary embolus

A thromboembolus fills a main pulmonary artery (red arrowhead). This closer view reveals a layered appearance, typical of a thrombus that formed in a large vein of the pelvis or lower extremity.

https://webpath.med.utah.edu/LUNGHTML/LUNG127.html
Accessed 01/10/2020

Pulmonary embolism

Area of infarction produced by a medium-sized thromboembolus to the lung. This infarction has begun to organize at the margins.

https://webpath.med.utah.edu/LUNGHTML/LUNG064.html
Accessed 01/10/2020

Pulmonary embolus



The fibrous bands of connective tissue across this recanalized pulmonary arterial branch indicate organization of a remote pulmonary thromboembolus.
If many pulmonary arteries are involved by this process, pulmonary hypertension could result.

https://webpath.med.utah.edu/LUNGHTML/LUNG120.html
Accessed 01/10/2020